Vorinostat (SAHA, MK0683)

Catalog No.S1047 Synonyms: SAHA, MK0683, suberoylanilide hydroxamic acid

Vorinostat (SAHA, MK0683) Chemical Structure

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 220 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 103 Publications

20 Customer Reviews

  • Activity of vorinostat in Jurkat and Peer T-ALL cell lines in an MTT cell viability assay. Cells were treated with increasing drug concentrations for 72 h. The data are plotted as the mean % of DMSO-treated control cells against the corresponding drug concentration. The error bars are the standard error. For each drug and cell line, 3-4 independent experiments were performed with 6 replicates at each drug concentration.

    Nature 2011 471, 235-9. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Differential effects of HDAC inhibitors on histone and tubulin acetylation. Immunofluorescence analysis of histone H3 (K9ac/K14ac) and tubulin acetylation in HeLa cells treated for 4 h with vehicle, SAHA (10 μM), tacedinaline (50 μM), PCI-24781 (20 μM. (a) Mapping of histone acetylation in K562 cells treated with HDAC inhibitors by LC-MS/MS. Cells were treated with TSA (10 μM), SAHA (5 μM), PCI-24781 (2 μM), tacedinaline (50 μM) for 6 h. Histones were extracted from cells and acetylated peptides were quantified after isobaric tagging.

    Nat Biotechnol 2011 29, 255-265. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Western blot analysis of histone H3 acetylation in the spleen of untreated and vorinostat-treated hNF-E2 tg mice (n = 4 of each genotype).

    J Exp Med 2012 209, 35-50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA down-regulates c-FLIP expression and increases the sensitivity of CaP cells to undergo apoptosis in the presence of bicalutamide (A) Bar graph illustrating the sub-G0/G1 cell population in 22Rv1 (left panel) and LNCaP (right panel) cells in the absence and presence of 10μM bicalutamide, administered as a single agent or in ombination with increasing concentrations of the HDAC inhibitor, SAHA. (B) Immunoblots demonstrating the single agent activity of bicalutamide or SAHA, or effect upon their combined administration on the expression of c-FLIP and/or the processing of PARP. Equal protein loading was confirmed by GAPDH. (C) Bar graph illustrating the effect of bicalutamide and SAHA upon the induction of caspase-8 or caspase-3/7 activity in 22Rv1 cells (left panel) and LNCaP cells (right panel). (D) Immunoblots characterizing the impact of SAHA and/or bicalutamide upon the induction of PARP cleavage, in the absence or presence of the pan-caspase inhibitor, ZIETD. ZIETD was incubated with the cells for 12 h prior to the experiment. All data points shown in (A) and (C) represent the mean ± S.E.M. value, calculated from four independent experiments.

    Clin Cancer Res 2012 18, 3822-33. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Analyses of efficacy, potency and IC50 of HDAC inhibitors point toward HDACs 1–3 as relevant candidates for beta cell protection. Ranking and raw data on ITF drugs (Table 3) and commercial HDAC inhibitors (Table 4) underlying the heat maps of Fig. 1 (A and B). The HDAC inhibitor compounds were tested using a HDAC activity kit and recombinant proteins to determine IC50 values on each individual HDAC (right part of the table). Each drug was further tested using Real-Time Cell Analysis (RTCA) to score their maximal effective concentration (ECmax) as well as the corresponding rescue percentage of cytokine treated INS-1 cells. The drugs were ranked according to % rescue. * DMSO alone controls were included in each experiment, but not shown here. The results indicate that the highest concentrations of DMSO used here (1:1,000) were slightly potentiating the proliferation of the cells. The effects observed in this group of compounds were ascribed to the DMSO.?

    Diabetologia 2012 55, 2421-2431. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Suberoylanilide hydroxyamic acid (SAHA) preserves CFP (+) expression in mouse optic nerves (MONs) from older mice. (a) CFP (+) mitochondria were longer and thicker in MONs from 12-month-old Thy-1 CFP mice (inset; scale bar = 2 μm). Oxygen–glucose deprivation (OGD) consistently reduced CFP pixel intensity in 12-month-old MONs despite longer and brighter CFP ( +) mitochondria (yellow arrows). (b) Blockade of AMPA/kain ate receptors with NBQX (30 μM), or pan-Histone deacetylase (HDAC) inhibition with SAHA (5 μM), effectively preserved CFP pixel intensity during OGD. The preservation of CFP (+) mitochondria correlates with protection of the CAP area during OGD and profound recovery.

    J Neurochem 2012 123 Suppl 2, 108-15. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • D and E, Regression of IL-13Ra 2-negative pancreatic tumors treated with SAHA and/or IL-13-PE. Mice were treated daily with i.p. injection of SAHA (25 mg/kg) from day 4 after tumor implantation for two weeks followed by i.t. injection of IL-13-PE (100 μ g/kg) from day 5 for two weeks. F and G, Regression of IL-13Ra 2-posotive pancreatic tumors (HS766T and MIA-PaCa2) treated with SAHA and/or IL-13-PE. The schedule of treatment was similar as in panel D and E. Statistical significances are shown by *: P < 0.05,†: P < 0.001.

    J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.

    IL-13Rα2 expression is upregulated in pancreatic tumors but not in organs of mice after treatment with HDAC inhibi tor, SAHA. A, qRT-PCR of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. Tumors were harvested next day after IL-13-PE treatment and total RNA extracted. Data shown is ratio of human IL-13Rα2/β-actin expression and multiplied by 1000 for convenience. Bars , SD of triplicate determinations. B, qRT-PCR of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Tissues were harvested at the same time point as in panel A and total RNA extracted. Data shown is ratio of mouse IL-13Rα2/β-actin expression and multiplied by 100 for convenience. C, IHC of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. D, IHC of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Liver, brain, kidney, pancreas, lung and spleen were fixed for immunostaining of mouse IL-13Rα2 as visualized by Alexa555. Nucleus was counterstained by DAPI.

    J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Proliferation o f HT29 and HCT116 cells after 48 h of butyrate or SAHA treatment. Proliferation measurements using the xCEL Ligence RTCA DP instrument (Roche) in cells treated with increasing doses of butyrate or SAHA, compared with control medium cells (0) (*P < 0.05). The mean ?SEM of three cell culture replicates is shown.

    Mol Carcinog 2012 52, 459-74. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA induces the down-regulation of cFLIP expression and promotes TRAIL-mediated activation of a mitochondrial-operated apoptotic pathway. a BT-474 cells were treated as indicated in Fig. 1 and the cells were then harvested to analyse caspase-8, Bid, caspase-9, caspase-3 and PARP expression, using GAPDH as the protein loading control. b BT-474 cells were treated with SAHA for 8 h at the doses indicated and subsequently, the cells were harvested and the apoptosis-related proteins were analysed in western blots as described in the "Materials and Methods". The results shown are representative of at least three independent experiments

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Treatment with SAHA sensitizes breast cancer cells to TRAILinduced apoptosis. BT-474 and MDA-MB-231 cells were incubated for 8 h with SAHA at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some of the cultures for an additional 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content as described in the "Materials and methods". The results show the mean and S.E.M. of three independent experiments

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA facilitates the Itch/AIP4-independent proteasomal degradation of cFLIP proteins in breast cancer cells. a BT-474 cells were treated with SAHA (5 μM) for 8 h in the presence or absence of the proteasome inhibitors MG132 or epoxomicin (at the doses indicated), and they were then harvested and the cFLIP content was analysed in western blots. b BT-474 cells were transfected with either the siRNA oligonucleotides targeting Itch/AIP4 or the non-targeting RNA oligonucleotide (scrambled) for 48 h as described in the "Materials and Methods". Subsequently, the cells were treated with SAHA (5 μM) for 8 h and then cFLIP and Itch/AIP4 expression was analysed in immunoblots

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • cFLIP down-regulation following SAHA treatment is responsible for the sensitization of breast cancer cells to TRAIL. a BT-474 cells were transfected with either different siRNAs directed against the cFLIP isoforms or the non-targeting RNA oligonucleotide (scrambled) as described in the "Materials and Methods". After 24 h, the cells were treated with TRAIL (500 ng/ml) for a further 15 h and apoptosis was then measured as the percentage of cells with subG1 DNA content. The results show the mean and S.E.M. of three independent experiments. To verify protein knockdown, cells were harvested 24 h after transfection and the cFLIP levels were assessed in immunoblots. b. BT-474 cells overexpressing Cflipl (pBABE-FLIPL) or control cells (pBABE) were treated with SAHA for 8 h at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some cultures for 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content and the results show the mean and range of two independent experiments. Western blots show the cFLIP levels after SAHA treatment in pBABE and pBABE-FLIPL cells.

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Vorinostat inhibits the tumor growth. NOD ⁄ SCID-B2m-/-mice were injected s.c. with 1×106 MyLa2059 cells into both flanks. When the mice had developed established palpable tumors treatment was initiated (day 1). The mice received either vehicle (black line) or 60 mg ⁄ kg vorinostat (grey line) i.p. five days a week. In total, there were four mice in the group receiving vehicle and three mice in the group receiving vorinostat. The length and width of the tumors were measured continuously until the experiment was terminated on day 20 post treatment initiation. The tumor volume was calculated using the formula V = (a×b2)/2, where a defines the length (mm) and b the width (mm) of the tumor. The histogram shows the average tumor volume per flank ± SEM. * denotes a significant difference (P < 0.05) in the average tumor volume per flank between mice treated with vehicle and vorinostat at the given time-point both by using a one-tailed two samples test with Welch, scorrection and a Mann-Whitney U test.

     

     

    Exp Dermatol 2010 19, 1096-1102. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • (a) Western blot of whole cell extracts demonstrates SAHA and NaB treatment result in increased levels of acetylated histone H3 compared to vehicle controls. (b) Light micrographs of HDACi/vehicle treated cultures illustrate the paucity of neurospheres in HDACi-treated cultures. (c) Quantitative analysis confirms SAHA and NaB inhibit the formation of neurospheres (diameter ≥ 50 μm) and increase the prevalence of small cell clusters (≥ 4 cell, diameter < 50 μm). (d) Flow cytometry using LIVE/DEAD cell stain confirms SAHA and NaB are minimally toxic compared to vehicle controls (n = 3). Scale bar = 100 μm.

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    (a) EdU flow cytometry of live cell-gated adult mouse NSCs demonstrates SAHA (**p < 0.01) and NaB (***p < 0.001) significantly inhibit DNA synthesis. (b) Analysis of DNA content by flow cytometry reveals significant accumulation of adult mouse NSCs in G1phase of the cell cycle following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (c) Correspondingly the proportion of cells in G2/M phase is significantly reduced following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (d) Fluorescence micrographs of HDACi/vehicle treated adult NSCs pulse-labeled with EdU for flow cytometry. Scale bar = 50 μm. Statistical comparisons performed using one-way ANOVA with post hoc Newman-Keuls multiple comparison tests.

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • (a) Immunofluorescence labeling of NeuN, GFAP and Olig2 cell fate markers reveals reduced expression of GFAP (*p < 0.001) and Olig2 (*p < 0.05) in adult mouse NSCs treated with SAHA for 48 hours under proliferation culture conditions and then induced to differentiate for 14 days in culture (two-way ANOVA with Bonferroni post-tests). (b) Western blot of β-catenin protein in nuclear and cytoplasmic fractions of adult mouse NSCs treated with HDACi/vehicle control under proliferation culture conditions. Gapdh and lamin A/C blots are included as loading controls. (c) SAHA and NaB do not significantly alter nuclear/cytoplasmic levels of β-catenin in adult mouse NSCs. Histogram of β-catenin Western blot signal intensities normalized to loading controls (n = 4).

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Morphological changes and histone H3 phosphorylation of HB cells treated with a combination of VX-680 and SAHA. HUH6 and HepT1 were incubated with VX-680 (6 μM) and SAHA (0.5 μM). Nuclei diameter (a) and cell diameter (b) were determined 72 h later by DAPI staining and microscopy. Data represent mean±SD of the diameters from 20 cells in each experiment. (* Two-way ANOVA, Bonferroni test, p \0.05). c Western blot analysis on HUH6 and HepT1 cells were carried out with an anti-phospho-Histone H3 (Ser 10) antibody (p-H3) 24 h after incubation with VX-680 (10 μM), SAHA (0.2 μM) or a combination of both. Controls were left untreated. Western blot analysis showed a decrease in p–H3 after treatment with VX-680 ( lane 2 ) relative to controls ( lane 1 ) and an increase when SAHA was added ( lane 3 ). For the combination of VX-680 and SAHA (lane 4 ) no p-H3 was detected.

    Pediatr Surg Int 2012 28, 579-89. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Vorinostat promotes C2C12 differentiation.In the image, the red is the myotube indicating differentiation ,the blue is the nuclei.

     

     

    Dr. Akihiko Yoshimura of Akihiko Yoshimura. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM SAHA was added.

     

     

    Dr. Zhang of Tianjin Medical University. Vorinostat (SAHA, MK0683) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
Targets
HDAC [1]
(Cell-free assay)
~10 nM
In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. [1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. [2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. [3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A20 MmTiT4lv[XOnIFHzd4F6 M4G4dlEhcA>? M3LibWROW09? NVLm[I5J[W62aT3ISGFEOSCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yOTJizszN MlzhNVE6PjB2OEm=
Friend leukemic cell MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX21NYJEPTBizszN NULJVWsxPzJiaB?= NF7GW|NFVVOR NGXiWllKSzVyPUCuPVkh|ryP MXyxNlExQTlzMx?=
K562 M3;sZmtqdmG|ZTDBd5NigQ>? NYq3XXlNPiCq NH;tbndFVVOR NV3NT4JnUW6qaXLpeIlwdiCxZjDoeY1idiCqaYP0c45mKGSnYXPleJlt[XOnIDjtbZh1fXKnIH;mJGhFSUNzIHHu[EBJTEGFMjmge4l1cCCLQ{WwJI9nKDBwMEGg{txO NF23W|MyOjRzOUO4NC=>
HT1080 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDZO|IhcA>? MWnEUXNQ M3WxUWlEPTB;Mj60JO69VQ>? MoC5NVIzPzBzN{W=
H1299 Mlv2T4lv[XOnIFHzd4F6 NFPhbmQzOCCvaX6= NWrYc21QTE2VTx?= NWPEbVRNUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KEiGQVOg[Y57gW2nIIfpeIghUUN3MDDv[kAxNjF7NDFOwG0> NFfvPYMyPDV{MUSyNi=>
H1299 MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu2[IM4OiCq NVf5[HF2TE2VTx?= NWrh[lExUUN3ME23MlI1KM7:TR?= MlnLNVQ2OjF2MkK=
HeLa NGjINFVMcW6jc3WgRZN{[Xl? NE\LdnI{OCCvaX6= NXL6Sm52UW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgbIl{fG:wZTDk[YFk\XS7bHHz[UB4cXSqIFnDOVAhd2ZiMD6yPEDPxE1? NYLFTFRjOTV4MEO5OFk>
LOX-IMVI MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e5U|Q5KGh? NFPKNohKSzVyPUGuN{DPxE1? NXy2UZBkOTV5MUW0O|A>
NCI-H226 NWXuN2N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUC0PEBp NWLOOoNGUUN3ME2yMlYh|ryP M{CzVVE2PzF3NEew
RXF-631L M1H4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnLOFghcA>? MnjOTWM2OD1{IN88US=> M4nQNlE2PzF3NEew
SNB-78 M1P0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DjVFQ5KGh? NGPFSnJKSzVyPUG2JO69VQ>? MUSxOVcyPTR5MB?=
St-4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICxZYs1QCCq NY\NUHduUUN3ME21MlIh|ryP M2CweFE2PzF3NEew
ARP1 MXzGeY5kfGmxbjDBd5NigQ>? NX7obmlEOiEQvF2= M122eVYhcA>? NHrqOWpKdmS3Y4Tpc44hd2ZiUEKxW2FHOSCpZX7lJIV5eHKnc4Ppc44> NWS3cXVEOTR5M{S4NFY>
CEM MmToT4lv[XOnIFHzd4F6 NV7wTZpIOSCq NEL2RVNFVVOR MlviTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkOzJO69VQ>? NHXNTZQyPjR{MEC2OC=>
HCT15 MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[0PEBp NEXPN5NIUTVyPUCuPFIh|ryP NHTITlAyPjd{M{KyOy=>
NCI-H23 NG[0OodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\kRVM1QCCq NEjSbndIUTVyPUCuPVIh|ryP M1u4V|E3PzJ|MkK3
GM15850 NH7ITYJMcW6jc3WgRZN{[Xl? NGftXWszNjVizszN M{S4Zlk3KGh? MlvDSG1UVw>? MVHJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDsfZNqdmViMUSgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV? M1:1dFE3QTJzM{[3
GM15850 NW[yRVhGU2mwYYPlJGF{e2G7 MYWyMlUh|ryP M{PzUFk3KGh? NGraSIpFVVOR MXnJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViNTDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>? NWLkeHRFOTZ7MkGzOlc>
GM15850 MWfLbY5ie2ViQYPzZZk> MWWyMlUh|ryP NFnFcW06PiCq NIHn[4RFVVOR MWjJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViMUKgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV? NVvOSYZHOTZ7MkGzOlc>
GM15850 MkflT4lv[XOnIFHzd4F6 MnnINk42KM7:TR?= NU\yeHBTQTZiaB?= M{LqcGROW09? MoGxTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSEOgcJl{cW6nIEmgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV? M13kNFE3QTJzM{[3
GM15850 M1rEOGtqdmG|ZTDBd5NigQ>? NYT4To5mOi53IN88US=> M{H0NVk3KGh? M3:3[mROW09? NHXyZo9KdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgPEBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?= NF3NR24yPjl{MUO2Oy=>
GM15850 M4rkeWtqdmG|ZTDBd5NigQ>? MlTxNk42KM7:TR?= MXi5OkBp NXjBSpVVTE2VTx?= Mny4TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEG2JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n NXLFNYF3OTZ7MkGzOlc>
U937 MXzGeY5kfGmxbjDBd5NigQ>? NHLYXGc2KM7:TR?= MojVNlQhcA>? NV24R3lzTE2VTx?= M3;NemNmdGxiY4njcIUh[XK{ZYP0JIJ6KGGlY4XteYxifGmxbjDheEBUN0d{L12gdIhie2V? MWCxO|AxPDdzOB?=
H661 NGWxN2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXUOFghcA>? NUn4NlY4UUN3ME2xJO69VQ>? NX60PYtCOTdzNUewNFk>
U937 NUHxW2gzTnWwY4Tpc44hSXO|YYm= M{HWVlUh|ryP M{jNW|I1KGh? MWTEUXNQ NVnuNHF{UW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDhZ4V1gWyjdHnvci=> MnjZNVc1PDd5NUC=
U937 M{[3eWZ2dmO2aX;uJGF{e2G7 NYXBbog3OSEQvF2= Ml\mNlQhcA>? MlvvSG1UVw>? NFi2e|BG\m[nY4Sgc44h[WyyaHGgeJVjfWyrbjDhZ4V1gWyjdHnvci=> M2DhWlE4PDR5N{Ww
RAW264.7 NYixXGdCTnWwY4Tpc44hSXO|YYm= M1HOfVExKM7:TR?= M3j1WlI1cA>? MXj3ZZRmeg>? MVfJcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJHRPTmGucHjhJJBzd2S3Y4Tpc44hf2m2aDDJR|UxKG:oIECuO|Yh|ryP MWixO|Q4PzVzOB?=
RAW264.7 NGHS[WFHfW6ldHnvckBCe3OjeR?= NGf6S28yOCEQvF2= MXGyOIg> NXHiVnFSf2G2ZYK= MlyzTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBPVyCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAyNjh6IN88US=> MVSxO|Q4PzVzOB?=
SC9 NFjDRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3TOFghcA>? MXjJR|UxRTBwNkC2JO69VQ>? Mo\rNVc2ODd{MUm=
ST14A MXTGeY5kfGmxbjDBd5NigQ>? MY[1JI5O MnzGO|IhcA>? MYDJcoNz\WG|ZTDpckBTTVOWL17SV2YhdVKQQTDlfJBz\XO|aX;u NX36XGVZOTd3NkW5PVM>
ST14A NFraWmhHfW6ldHnvckBCe3OjeR?= MX21JI5O M1j5eFczKGh? M1K2XWlv[3KnYYPlJIlvKEV{RkGgcXJPSSCneIDy[ZN{cW:w NEfsTWYyPzV4NUm5Ny=>
PANC1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\XNlEh|ryP MULJR|UxRTBwNEWg{txO MWWxO|U5QDd2NB?=
PANC1 NVG3[pdWTnWwY4Tpc44hSXO|YYm= M1HRdlEh|ryP M{jidFI1KGh? NILCUIpKdmO{ZXHz[UBqdiCyMkHXRWYyN0OLUEGg[4Vv\SCneIDy[ZN{cW:w MkDmNVc2QDh5NES=
PANC1 M1\mS2Z2dmO2aX;uJGF{e2G7 MXGxJO69VQ>? MoTiNlQhcA>? NYDl[2hxUW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44> NUe3TIlLOTd3OEi3OFQ>
PT45 NHHDOJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfI[G9KSzVyPUSg{txO MUCxO|U5QDd2NB?=
ACHN MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYmyNUBp NWjvSYxpT0l3ME2wMlY2KM7:TR?= NYr4TlB1OTd4NkK2NFY>
PC3 NF73XHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\xNlEhcA>? MX7HTVUxRTBwN{Gg{txO NX3CVGljOTd4NkK2NFY>
A431 MVPDfZRwfG:6aXOgRZN{[Xl? MWK3NkBp M{TPS2lEPTB;ND6yJO69VQ>? MmPiNVc3QTF5NkO=
Cal27 MVfDfZRwfG:6aXOgRZN{[Xl? MUm3NkBp NVfwVmYxUUN3ME2zMlIh|ryP MYGxO|Y6OTd4Mx?=
CCRF-CEM MoqyR5l1d3SxeHnjJGF{e2G7 NHTSN4Q4OiCq MlXKTWM2OD1yLkig{txO NIjnU3IyPzZ7MUe2Ny=>
EOL1 MlzxR5l1d3SxeHnjJGF{e2G7 NGj1U3I4OiCq MVnJR|UxRTFizszN MVOxO|Y6OTd4Mx?=
Hec-1-A NGrQNmhEgXSxdH;4bYMhSXO|YYm= NHfh[Jg4OiCq MWrJR|UxRTFizszN MVuxO|Y6OTd4Mx?=
HeLa MWLLbY5ie2ViQYPzZZk> Mkf1NVAh|ryP NHrTO4M{OCCvaX6= NGTsepNFVVOR NHnNcm9KdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGhFSUNzIIfpeIghUUN3MDDv[kAxNjB{IN88US=> NHjQO20yPzZ7MUe2Ny=>
RKOp21 NHLqXJREgXSxdH;4bYMhSXO|YYm= MlHDO|IhcA>? MWnJR|UxRTFwN{[g{txO Mn\iNVc3QTF5NkO=
Saos2 NFi3S5VEgXSxdH;4bYMhSXO|YYm= NHmwOYg4OiCq NHzVfHRKSzVyPUKuN{DPxE1? M{eyZlE4PjlzN{[z
SK-OV-3 M{jTd2N6fG:2b4jpZ{BCe3OjeR?= NH\OXIs4OiCq M{G5VGlEPTB;Mj6yJO69VQ>? M3H6[|E4PjlzN{[z
U87MG M{joSGN6fG:2b4jpZ{BCe3OjeR?= NYnsbFIyPzJiaB?= NWL1U29qUUN3ME2xNUDPxE1? MYixO|Y6OTd4Mx?=
NUGC3 NHrZeW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\zc3M2KM7:TR?= MkL6NlQhcA>? NIDUN2JIUTVyPUKuO|kh|ryP M1;CW|E4QTB2OESz
CCD1059SK M2DaWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7PTWM2OD12Mz61JO69VQ>? M4PNXlE5OjR5NUW0
HepG2 NITYOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMECwOkDPxE1? M2TLWFE5OjR5NUW0
HT1080 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\zTWM2OD1yLkCwNlQh|ryP M1;BWVE5OjR5NUW0
SKBR3 NITERWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLETWM2OD1yLkig{txO MkHGNVgzPDd3NUS=
SNB78 M163dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLxSWM2OD1zNjFOwG0> M2nadFE5OjR5NUW0
SQ20B MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TNeGlEPTB;MzFOwG0> MXOxPFI1PzV3NB?=
St4 NF7IbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjWVo51TUN3ME21MlIh|ryP MV:xPFI1PzV3NB?=
MCF7 MV7GeY5kfGmxbjDBd5NigQ>? NUDZbpV6OTBizszN MUe4JIg> MmjUSG1UVw>? NYHRZoJtUW6mdXP0bY9vKG:oIIT1ZpVtcW5iaInw[ZJi[2W2eXzheIlwdg>? NVPOO29sOTh{NkmyNlY>
HEK293 MUXLbY5ie2ViQYPzZZk> NYLs[2JKOSCq NG\ORpdFVVOR Mnv3TY5pcWKrdHnvckBw\iCKRFHDNUB4cXSqIFnDOVAhd2ZiMD6wN{DPxE1? MnPKNVg{ODh3NkO=
HEK293 M3vXfWtqdmG|ZTDBd5NigQ>? NYH5OGZDOSCq MV7EUXNQ NFvqWpJKdmirYnn0bY9vKG:oIFjERWM{KHerdHigTWM2OCCxZjCwMlA2PyEQvF2= MlHvNVg{ODh3NkO=
G401 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUC3NkBp MXXEUXNQ MkLXTWM2OD1zIN88US=> MUmxPFM4ODN5Mx?=
HeLa NHHZNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn4fHZzPzJiaB?= MkPZSG1UVw>? M4nRUmlEPTB;MD60OkDPxE1? NIXKfokyQDN5MEO3Ny=>
Human renal epithelial cell NHW4d21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX63NkBp NYLEfXc1TE2VTx?= MlTmTWM2OD1zNDFOwG0> MUixPFM4ODN5Mx?=
U937 M{i5bmZ2dmO2aX;uJGF{e2G7 NFLmXZM2KM7:TR?= NGXFNlYzPCCq Mk\JTY5lfWO2aX;uJI9nKGirc4TvcoUhUDRiaInw[ZJi[2W2eXzheIlwdg>? M4DHTlE5OzhzMkO4
U937 NILtWVhHfW6ldHnvckBCe3OjeR?= MX21JO69VQ>? MXqyOEBp NIDrSpVKdmS3Y4Tpc44hd2ZiYXzwbIEhfHWkdXzpckBpgXCncnHj[ZR6dGG2aX;u NHz6PWYyQDN6MUKzPC=>
U937 NWPlfGxsTnWwY4Tpc44hSXO|YYm= NX3Yd5p{PSEQvF2= MXKyOEBp NVLRRo9qUW6mdXP0bY9vKG:oIICyNUBmgHC{ZYPzbY9v NI[wSpkyQDN6MUKzPC=>
U937 MnHXSpVv[3Srb36gRZN{[Xl? MmmyOUDPxE1? M37XRlI1KGh? NGLQcnRKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m| Mk[5NVg{QDF{M{i=
U937 NWL1U|QyTnWwY4Tpc44hSXO|YYm= NYnITm9QPSEQvF2= NHyy[FMzPCCq MVvJcoR2[3Srb36gc4Yh\3KjboXsc4N6fGmlIHTp[oZmemWwdHnheIlwdg>? M3PvVlE5OzhzMkO4
U937 NW\zcI1jU2mwYYPlJGF{e2G7 M2Pnc|Uh|ryP MUeyOEBp NGfjNI1KdmirYnn0bY9vKG:oIHj1cYFvKEiGQVOx M33tflE5OzhzMkO4
U937 NYPiR4lyU2mwYYPlJGF{e2G7 NUHkb45xPSEQvF2= NIHFeGgzPCCq M3:4UWlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{S= M2HXU|E5OzhzMkO4
HEK-TE M4rqW2Z2dmO2aX;uJGF{e2G7 Mor1OUDPxE1? M331XFZp NHTuUI1FVVOR MU\JcoNz\WG|ZTDpckBpcXO2b37lJGg{KGGlZYT5cIF1cW:w MYexPFQ{PDF2NB?=
HPDE6c7 M4rqO2N6fG:2b4jpZ{BCe3OjeR?= MX61NEDPxE1? NHLr[VE4OiCq NVX5UW5PTE2VTx?= M{jlZ2lEPTB;MT6zJO69VQ>? M3zkNFE5PDl2NE[z
Human microvascular epithelial cell Ml:0R5l1d3SxeHnjJGF{e2G7 M2HD[|UxKM7:TR?= M4C3S|czKGh? NXnQ[ZEyTE2VTx?= NYq2V3Y5UUN3ME2xMlMh|ryP NW[zW4xJOTh2OUS0OlM>
Hup T3 MlTTR5l1d3SxeHnjJGF{e2G7 M{ewdVUxKM7:TR?= NWjmfGhEPzKq NXzTXHAzTE2VTx?= MUfJR|UxRTBwODFOwG0> Mnz0NVg1QTR2NkO=
Mia Paca2 M3PGSGN6fG:2b4jpZ{BCe3OjeR?= MmLsOVAh|ryP M{\Lb|czcA>? NWjSR4xsTE2VTx?= MlznTWM2OD1zLkGg{txO MV2xPFQ6PDR4Mx?=
Panc 04.03 NXXRTmt5S3m2b4TvfIlkKEG|c3H5 M3P2Z|UxKM7:TR?= MWK3Nog> NE\VdY5FVVOR MkPpTWM2OD1zLkKg{txO Mn;qNVg1QTR2NkO=
SU 86.86 MU\DfZRwfG:6aXOgRZN{[Xl? Mn7xOVAh|ryP M{HRR|czcA>? MknSSG1UVw>? NWS0Rox5UUN3ME2xMlMh|ryP MVWxPFQ6PDR4Mx?=
HEK293 MmPxT4lv[XOnIFHzd4F6 MUCzJIg> MXTJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFjERWM3KGW6cILld5Nqd25id3n0bEBKSzVyIH;mJFAvODF7IN88US=> M1fqPFE5PTV6Nk[5
HeLa NEP6bJNMcW6jc3WgRZN{[Xl? NUHEcpAxOiCq MV7Jcohq[mm2aX;uJI9nKG63Y3zlZZIhUESDQzD3bZRpKEmFNUCgc4YhOC5yOEOg{txO MYixPFU2QDZ4OR?=
RAW264.7 NYLuNJlTTnWwY4Tpc44hSXO|YYm= MYCyJO69VQ>? NWP6bnZHOy53IHi= NX7adI02TE2VTx?= MVPBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBRdGG|bX;kbZVuKG[jbHPpdIFzfW1iaX7m[YN1\WRid3n0bEBKSzVyIH;mJFAvOTFizszN NULke3RKOTh4NES5Olk>
NB4 MlPuOFhp MljHSG1UVw>? MVLJR|UxRTBwNjFOwG0> NWHYPJVQOTh5MkOzOFk>
HEK293 NYrxOVZJTnWwY4Tpc44hSXO|YYm= NWixWYN[OTBizszN M1:0VlI1KGh? NWiyZ|V1TE2VTx?= M1iwNmFkfGm4YYTpc44hd2ZibX;1d4UhX262M3Ggd4lodmGuaX7nJIV5eHKnc4Pl[C=> NGXrW3AyQTB{Mk[3OS=>
HCT116 MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XNeFczcA>? M4r6cmROW09? MlHhTWM2OD1yLkOxJO69VQ>? M4G1RlE6ODh2Mkm0
HeLa M{D3[mtqdmG|ZTDBd5NigQ>? NEfEbnczKM7:TR?= NYj1c2c1OzBibXnu NUPySmtbTE2VTx?= M{DFcWlvcGmkaYTpc44hd2ZiSFTBR|IhcW5iaIXtZY4hUGWOYTDj[YxteyC5aYToJGlEPTBib3[gNE4yKM7:TR?= NUXzU3hFOTlyOESyPVQ>
IGROV1 NWLtNYx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfiRpFEPzJiaB?= NIf1b4lFVVOR M{G4OmlEPTB;Mj6yJO69VQ>? NU\rZ4N[OTlyOESyPVQ>
IGROV1 NW\HUXdvU2mwYYPlJGF{e2G7 MonmOUDPxE1? NXnEcYhtOjRiaB?= NV;xZo1xTE2VTx?= NWrGcJBzUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IIC1N{Bi[2W2eXzheIlwdg>? NFPkWJQyQTB6NEK5OC=>
IGROV1 MYLLbY5ie2ViQYPzZZk> NFzFdG0yOCEQvF2= MXq0JIg> MWXEUXNQ MkXOTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGirc4TvcoUuUDRiYXPleJlt[XSrb36= MVWxPVA5PDJ7NB?=
IGROV1 NUDybHQ3U2mwYYPlJGF{e2G7 M1nVO|ExKM7:TR?= M4\oSFQhcA>? M1rFR2ROW09? MVXJcohq[mm2aX;uJI9nKEiGQVO2JIF{e2W|c3XkJIF{KGGucHjhMZR2[nWuaX6gZYNmfHmuYYTpc44> M3PmXVE6ODh2Mkm0
T24 M{TyemtqdmG|ZTDBd5NigQ>? MnPhN{Bp NHuxV4NKdmS3Y4Tpc44hd2ZiaHnzeI9v\SCKMzDhZ4V1gWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6xNkDPxE1? NF;4OFMyQTB6NEO5OS=>
T24 MUTLbY5ie2ViQYPzZZk> MXuzJIg> MUDJcoR2[3Srb36gc4Yh[WyyaHGgeJVjfWyrbjDhZ4V1gWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6yOUDPxE1? NY[4TndKOTlyOESzPVU>
HeLa MUjLbY5ie2ViQYPzZZk> MkTjNVUhdWmw MXLEUXNQ M{ThOGlvcGmkaYTpc44hd2ZiSFTBR|Yh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFAvODh3NTFOwG0> M1XzZ|E6ODl|OEi0
HeLa Ml\lT4lv[XOnIFHzd4F6 M{DnSlE2KG2rbh?= NYfmN21lTE2VTx?= NIjEeplKdmirYnn0bY9vKG:oIFjERWM5KG[{b32gcpVkdGWjcjDlfJRz[WO2IIfpeIghUUN3MDDv[kAyNjh4IN88US=> MonjNVkxQTN6OES=
NCI-H69 Ml3ZR5l1d3SxeHnjJGF{e2G7 NVXlNIdjPzJiaB?= NGniZlZFVVOR NHrGO4tKSzVyPUKuNFYh|ryP MlSwNVkxQTN6OES=
SKMES1 NUn1bYQ2S3m2b4TvfIlkKEG|c3H5 MmrXO|IhcA>? NY\CVWg3TE2VTx?= M3TFZ2lEPTB;Mj60NkDPxE1? M{XhNlE6ODl|OEi0
S2 MnXET4lv[XOnIFHzd4F6 M3PPXlAvOS1zMDFOwG0> NH31TIgyKGh? MWLJcohq[mm2aX;uJI9nKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDISGFEOSCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvODV7IN88US=> NVvQe|ZiOTl|MUe0OVA>
SHSY5Y MYTLbY5ie2ViQYPzZZk> MYSxNEDPxE1? MlTyOFghcA>? NUDHdXN7TE2VTx?= M2O3OGlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD61JO69VQ>? M4rKRVE6OzR2MUe1
SHSY5Y M2C2PGN6fG:2b4jpZ{BCe3OjeR?= NXW3cGxEOTBizszN MmHGOFghcA>? MYDEUXNQ NIPXbG1KSzVyPUKg{txO MX6xPVM1PDF5NR?=
DMS114 MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ewOFQ5KGh? NITNdHNIUTVyPUKuPUDPxE1? M1fX[lE6PDF7MkC1
HBC5 Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7qRohDPDhiaB?= NWXxV49CT0l3ME2xO{DPxE1? NFj1VYsyQTRzOUKwOS=>
SNB78 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\YWnc1QCCq M2qwRWdKPTB;MU[g{txO MWWxPVQyQTJyNR?=
HeLa NV3EZZV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUm3NkBp M3m5N2ROW09? MlLVTWM2OD1yLkS2JO69VQ>? MY[xPVQ1OTh2Nh?=
BHK NI\GWZVMcW6jc3WgRZN{[Xl? NG\w[os2KM7:TR?= NFrDbYUzPCCq M{jv[mROW09? MXzJcohq[mm2aX;uJI9nKEiGQVO3JIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwcIF{dWFibXXtZpJidmViRnTlcJRiPTB6IFPGWHIheHKxdHXpci=> MUixPVk3Pjd6OR?=
CFBE41o- Mo\pT4lv[XOnIFHzd4F6 NU\Qfo1iPSEQvF2= MlfFPEBp NF\1TVlFVVOR NXLWNXBjUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHj5dIVz[WOndInsZZRqd25ib3[gbIl{fG:wZTDINy=> MoTMNVk6PjZ5OEm=
CFBE41o- MnjlT4lv[XOnIFHzd4F6 NHHtOWw2KM7:TR?= MWq0JIg> MofJSG1UVw>? NUPvfJl[UW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJI12fGGwdDDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKGyndnXs M1jvXlE6QTZ4N{i5
CFBE41o- MlW1T4lv[XOnIFHzd4F6 M3\WTFEh|ryP NXH0TmE{OSCq NFvPOHlFVVOR MVrJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iQ1\UVkBxem:2ZXnuJIxmfmWu NWTUdlNEOTl7Nk[3PFk>
Primary bronchial epithelial cell MVLLbY5ie2ViQYPzZZk> M2S0UVEh|ryP MlPNNlQhcA>? MkPoSG1UVw>? NUnS[5N2UW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhdXW2YX70JGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5iYYDpZ4FtKHO3cn\hZ4UhdG:lYXzpfoF1cW:w MYKxPVk3Pjd6OR?=
CFBE41o- M2HweGtqdmG|ZTDBd5NigQ>? NUT4[HplOSEQvF2= M2nxUVUh\GG7cx?= NV7jS2dLTE2VTx?= MUPJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIIP0ZYJqdGm8YYTpc44hd2ZiRnTlcJRiPTB6IFPGWHIheHKxdHXpci=> MX6xPVk3Pjd6OR?=
CFBE41o- M4nVTGtqdmG|ZTDBd5NigQ>? NYK2WIZIOSEQvF2= NVPudpN3OjRiaB?= M2W4dmROW09? NHvLUIFKdmirYnn0bY9vKG:oIFjERWM4KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5idILh[oZq[2urbne= NHnydXgyQTl4Nke4PS=>
CFBE41o- M4nId2tqdmG|ZTDBd5NigQ>? M2jDR|Uh|ryP MlPQNlQhcA>? NF;2R2lFVVOR MnXKTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDyZZRmKG:oIH3heJVz[XSrb36gc4YhS0[WUjDwdo91\WmwIITvJIl1eyCpbInjc4Zwem1? M1fzO|E6QTZ4N{i5
CFBE41o- NIPOcYVMcW6jc3WgRZN{[Xl? Mny2OUDPxE1? NXzNXnF3OjRiaB?= NFfkSGRFVVOR NF;ZVmxKdmirYnn0bY9vKG:oIFjERWM4KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJJN1[WKrbHn0fUBw\iCIZHXseIE2ODhiQ1\UVkBxem:2ZXnu NF\DSVYyQTl4Nke4PS=>
CFBE41o- NGHycpNMcW6jc3WgRZN{[Xl? NWH2ZWJDPSEQvF2= MkD5NlQhcA>? MnXMSG1UVw>? NYT2XINPUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDjc5Jz\WO2aX;uJI9nKG23dHHueEBH\GWudHG1NFghS0[WUjD0doFn\mmla3nu[{B1dyClZXzsJJN2em[jY3WgZZMh\2y7Y3;mc5Ju M4C5eFE6QTZ4N{i5
Primary bronchial epithelial cell NHLaZlBMcW6jc3WgRZN{[Xl? MYS1JO69VQ>? M1G2fVI1KGh? NY\xT5pMTE2VTx?= M3jISWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4h[XCrY3HsJJN2em[jY3WgcI9k[WyrenH0bY9v Mmf6NVk6PjZ5OEm=
Primary bronchial epithelial cell MnT3T4lv[XOnIFHzd4F6 M{\tb|Eh|ryP MU[5OkBp M{jBRWROW09? NEft[2ZKdmirYnn0bY9vKG:oIFjERWM4KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJJNpd3K2IHPpdoN2cXRiY4XydoVvfHN? NWfsXmJDOTl7Nk[3PFk>
BxPC3 NEjRT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXTXoc4OiCq NVLVboE5UUN3ME2yMlch|ryP Mn\iNlAyPDN5N{i=
CAL27 M2HX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT2SlNWPzJiaB?= NWXVO5VLUUN3ME2zMlczKM7:TR?= MnTCNlAyPDN5N{i=
Capan1 MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrVNXhHPzJiaB?= MkjOTWM2OD15LkOg{txO NEXGTmwzODF2M{e3PC=>
HCC827 NUPyZ49CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn0VHc4OiCq M{TsPGlEPTB;MT64JO69VQ>? NFi2[G4zODF2M{e3PC=>
LNCAP NGC5WXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4qzcVczKGh? Ml36TWM2OD1yLkW4JO69VQ>? MlTlNlAyPDN5N{i=
NCI-H2122 NFPQcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVO3NkBp NWmyUFhHUUN3ME23MlUh|ryP M4W2OFIxOTR|N{e4
NCI-H358 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPQN4xPPzJiaB?= MWjJR|UxRTJwNTFOwG0> MoLxNlAyPDN5N{i=
SCC15 NYXHe2I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzkPIw4OiCq NIG2UlFKSzVyPUKuOFkh|ryP NWnLbmw{OjBzNEO3O|g>
SCC25 M4[4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7hO|IhcA>? MmDBTWM2OD1zLkmzJO69VQ>? MnvPNlAyPDN5N{i=
SKHEP1 M2e5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjmO|IhcA>? M4LafWlEPTB;Mz60OkDPxE1? NVG1ZXN5OjBzNEO3O|g>
BJ NWnzXXVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vyelExOCEQvF2= NXjvNlh2PDhiaB?= M1TkRWROW09? Mn3TS5Jwf3SqIHnubIljcXSrb36gZZQhOC5yNTD0c{AyODBidV2= MWeyNFE1Ozh2MB?=
MUF M4rBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnOZ5gyODBizszN NWG3VWw2PDhiaB?= M3\COWROW09? M2HXeGdzd3e2aDDpcohq[mm2aX;uJIF1KDBwMEWgeI8hOTByIIXN NXXnRoNVOjBzNEO4OFA>
Caco-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXJO5gyODBizszN M3nMZlQ5cA>? MWTEUXNQ NXzFO|d3UUN3ME24MlEh|ryP MWSyNFE1Ozh2MB?=
Caco-2 MYXLbY5ie2ViQYPzZZk> MnX4OUDPxE1? Mn2wOEBp MVLEUXNQ M3;0d2lv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIhqe3SxbnWgZYNmfHmuYYTpc44hUUN3MDDv[kAxNjB|NzFOwG0> MVSyNFE1Ozh2MB?=
Caco-2 NF2xO41McW6jc3WgRZN{[Xl? M4izXFAvOzF4IH7NJJRwKDNzLk[g{txO NFzYdJk1KGh? NUXDS4JOTE2VTx?= Ml7JSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUNzIIfpeIghUUN3MDDv[kAxNjFzOTFOwG0> M4r1VFIxOTR|OESw
Caco-2 NVPUd49vU2mwYYPlJGF{e2G7 M17YTVAvOzF4IH7NJJRwKDNzLk[g{txO M3fUU|QhcA>? NUK4R4oyTE2VTx?= MUHFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzNid3n0bEBKSzVyIH;mJFAvOTR5IN88US=> MUWyNFE1Ozh2MB?=
Caco-2 MUXLbY5ie2ViQYPzZZk> NFPVc3M3NjN{IH7NJJRwKDZ|MjFOwG0> MXq0JIg> NVHhXmJuTE2VTx?= MV\FfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzVid3n0bEBKSzVyIH;mJFEzNjZizszN MYCyNFE1Ozh2MB?=
Caco-2 NYflV5NwU2mwYYPlJGF{e2G7 NH21UWY3NjN{IH7NJJRwKDZ|MjFOwG0> NVf0NI1kPCCq M4TKRmROW09? Mkf5SZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN5IIfpeIghUUN3MDDv[kA1OSEQvF2= NUPRdXZzOjBzNEO4OFA>
Caco-2 NWrCR2pzU2mwYYPlJGF{e2G7 MV:wMlMyPiCwTTD0c{A{OS54IN88US=> M3L5ZlQhcA>? MlzDSG1UVw>? MX7FfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzZ? NVLGbXA6OjBzNEO4OFA>
HepG2 NU\zcI14U2mwYYPlJGF{e2G7 MWq1JO69VQ>? M3f0WVZp M2DnbmROW09? M{PodGlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIhqe3SxbnWgZYNmfHmuYYTpc44> NFvaOlczODF2M{i0NC=>
HepG2 M4\rbWtqdmG|ZTDBd5NigQ>? M4XlOlUh|ryP NIPzVXc3cA>? NWXKRVkzTE2VTx?= MnPiTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgbIl{fG:wZTDofZBmemGlZYT5cIF1cW:w M2jyPVIxOTR|OESw
HepG2 M2\PSWtqdmG|ZTDBd5NigQ>? M2LSdFUh|ryP NWDX[XBKPmh? NVnSd3BDTE2VTx?= MlHWTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgZYxxcGFvdIXieYxqdiCjY3X0fYxifGmxbh?= MWeyNFE1Ozh2MB?=
HepG2 MYTLbY5ie2ViQYPzZZk> M2fsUlUh|ryP MkTKOog> MVrEUXNQ M1\ZeGlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJGg{N0h2IHjpd5RwdmViYXPleJlt[XSrb36= MkjRNlAyPDN6NEC=
COLO205 NWrlPWFLU2mwYYPlJGF{e2G7 MVuxNEDPxE1? NH3rNZMzPCCq NHrrUFdFVVOR MX3Jcohq[mm2aX;uJI9nKEiGQVOxJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDobZN1d26nIFizJIFk\XS7bHH0bY9vKHerdHigTWM2OCCxZjCyMlIh|ryP M3jJeVIxPDVzM{e4
SCC4 NX:3O3pMU2mwYYPlJGF{e2G7 NYHqSVN{OSEQvF2= MnLwNlRp NGe0RXZKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6geJVjfWyrbjDhZ4V1gWyjdHnvci=> NEPGT5IzODR3MkKyOS=>
SCC4 NILhRmRMcW6jc3WgRZN{[Xl? NWLudFNbOSEQvF2= NX;qdmtQOjSq M2\h[2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIHHj[ZR6dGG2aX;u MnvnNlA1PTJ{MkW=
SCC4 MVvGeY5kfGmxbjDBd5NigQ>? MUixJO69VQ>? M3;0ZlUhdWmw M3PVeWFod26rc4SgZYN1cX[rdImgZZQhXkSUIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCFWWCyOEBo\W6nIHX4dJJme3Orb36= NHT0RmgzODR3MkKyOS=>
NB4 NWLoRVlnTnWwY4Tpc44hSXO|YYm= Mn3BOUDPxE1? MXiyOEBp Mkj1SG1UVw>? MYHD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjY3P1cZVt[XSrb36gZZQheHKnLVexJJBp[XOn MnnzNlA1QTF2NEC=
NB4 NVrNeYNXU2mwYYPlJGF{e2G7 MUK1JO69VQ>? MYiyOEBp MmjXSG1UVw>? M3jp[mlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4V1gWyjdHWgeJVjfWyrbjDs[ZZmdA>? NVe1cmxWOjB2OUG0OFA>
NB4 NIniSXhHfW6ldHnvckBCe3OjeR?= NV;CNmI4PSEQvF2= Ml[0NlQhcA>? NHP2U2RFVVOR MVzJcoR2[3Srb36gc4YheDJzV1HGNU9EUVBzIHX4dJJme3Orb36= MYKyNFQ6OTR2MB?=
NB4 MU\LbY5ie2ViQYPzZZk> MmC2OUDPxE1? MoPNNlQhcA>? NEnr[lRFVVOR NGnjZ4ZKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{Bi[2W2eXzheIlwdg>? NEf3O3UzODR7MUS0NC=>
NUGC3 MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvMOGJjT0l3ME2yMlk1KM7:TR?= MXGyNFg2ODl5MR?=
A549 Mn7JSpVv[3Srb36gRZN{[Xl? NGnYdos2KM7:TR?= Ml7JN{Bp M1q3UmROW09? M4TFNGlv\HWldHnvckBw\iCjdYTvdIhi\3liaX6gbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCOQ{PJTS=> NV7WU5prOjB6NUWyNFg>
HUT78 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PlOVczKGh? NFmwN|NFVVOR NFzGU2ZIUTVyPUCuN{DPxE1? MmnXNlA5QDR{MEi=
U937 NUH6NZhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W0d|czKGh? M4XhW2ROW09? NYjjXFBET0l3ME2wMlM6KM7:TR?= M{XsclIxQDh2MkC4
A431 MlXDR5l1d3SxeHnjJGF{e2G7 M3\Jb|czKGh? M4Gwe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMhd3[ncnX4dJJme3OrbnegSWdHWiC5aYToJGlEPTBib3[gOE4zKM7:TR?= NEnzZXMzOTB6ME[yPS=>
A549 NXjZbFlRS3m2b4TvfIlkKEG|c3H5 MWO3NkBp M4XRfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMhd3[ncnX4dJJme3OrbnegTGRCSyC5aYToJGlEPTBib3[gNU45KM7:TR?= MlTkNlExQDB4Mkm=
CAL27 MmqzR5l1d3SxeHnjJGF{e2G7 M1fDV|czKGh? NV30WGpJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0GOMkegZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjD3bZRpKEmFNUCgc4YhOy5{IN88US=> M2fn[lIyODhyNkK5
HeLa NGq3V5BEgXSxdH;4bYMhSXO|YYm= MVO3NkBp NIGxZ2ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KG:4ZYLlfJBz\XO|aX7nJGhFSUNid3n0bEBKSzVyIH;mJFEvPSEQvF2= NFj0OoMzOTB6ME[yPS=>
Sf21 MXfLbY5ie2ViQYPzZZk> NXPpcY1{OyCq MWLJcohq[mm2aX;uJI9nKE[uYXegeIFo\2WmIHj1cYFvKHKnY3;tZolv[W62IFjERWM5KGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU4zKM7:TR?= M{jmfFIyODhyNkK5
SKBR3 MYHDfZRwfG:6aXOgRZN{[Xl? MnXPO|IhcA>? NIDo[W5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0KUMzDj[YxteyCxdnXy[ZhxemW|c3nu[{BJTVJ{IIfpeIghUUN3MDDv[kAzNjZizszN M4rIVFIyODhyNkK5
SKOV3 Mle4R5l1d3SxeHnjJGF{e2G7 MoW1O|IhcA>? MmnoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMhd3[ncnX4dJJme3OrbnegTGVTOiC5aYToJGlEPTBib3[gNk4zKM7:TR?= NVjwbItiOjFyOEC2Nlk>
COR-L23 M3nocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jleVExKM7:TR?= MUS3NkBp M2H3OWROW09? NWf2[HpET0l3ME2xMlEh|ryP MVGyNVA5ODZ2Nx?=
DU145 MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj2e2QyOCEQvF2= M3XQSlczKGh? MX7EUXNQ MU\HTVUxRTFwMEWg{txO MUmyNVA5ODZ2Nx?=
LoVo M2G1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPadYcyOCEQvF2= M1jQ[VczKGh? M3LsUWROW09? NFrLfXhIUTVyPUGuO{DPxE1? MX2yNVA5ODZ2Nx?=
MCR5-SV2 MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXThZYVOOTBizszN M3njWVczKGh? NFv4VJBFVVOR Mn6xS2k2OD1{LkGg{txO NGHjO4IzOTB6ME[0Oy=>
HCT116 NUfXfmdHU2mwYYPlJGF{e2G7 M{L2eFMxKM7:TR?= MYmzNEBp Ml[zSG1UVw>? NUnYdIV7UW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4Yh[WyyaHGteJVjfWyrbjDhZ4V1gWyjdHnvci=> NGnPcGszOTB6ME[0Oy=>
HCT116 NYPCdXhCU2mwYYPlJGF{e2G7 NUnnOmxsOzBizszN Mmn4N|AhcA>? MUnEUXNQ MYXJcohq[mm2aX;uJI9nKEiGQVOxJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDobZN1d26nIFizT|kh[WOndInsZZRqd25? MYOyNVA5ODZ2Nx?=
U937 M2PSW2tqdmG|ZTDBd5NigQ>? NYTI[ZJwPSEQvF2= NV\nTnNLOjRiaB?= MlTkSG1UVw>? NYH3[XR6UW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{m= NGXkSIczOTJ7MkS5Ni=>
U937 NXLITJFXU2mwYYPlJGF{e2G7 NXPBd2plPSEQvF2= MkC5NlQhcA>? MXfEUXNQ NWPtNlF1UW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{G4 Mk\pNlEzQTJ2OUK=
U937 M1zIVWtqdmG|ZTDBd5NigQ>? MWK1JO69VQ>? M{XhNFI1KGh? M3rnPGROW09? MX3Jcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO|ZYPz[YQh[XNiaX7jdoVie2Vib3[gdIFvNWGlZYT5cIF1\WRiaHnzeI9v\SCKNDDs[ZZmdA>? NUnMd|J7OjF{OUK0PVI>
U937 NEjwVGlMcW6jc3WgRZN{[Xl? M{T5flUh|ryP NFXGc4cyPSCvaX6= MVTEUXNQ NIHKXoVKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4YhcGm|dH;u[UBJOyCjY3X0fYxifGmxbjDs[ZZmdA>? NXS4[XdZOjF{OUK0PVI>
A2780 NILMZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLOV4Q6PiCq NFPIc2RFVVOR NF;Cc5RKSzVyPUGuOlIh|ryP M{TOTFIyPjN2NEOw
COLO205 M1znN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1q1clk3KGh? MYTEUXNQ NHK0fVJKSzVyPUKuNVIh|ryP NXrmWIJSOjF4M{S0N|A>
Hep3B MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn1N2VyPDhiaB?= NIfwXnVFVVOR MmT5S2k2OD1zLkKxJO69VQ>? NX\DTGI4OjF5MUKxOFY>
GM11272 MmfnSpVv[3Srb36gRZN{[Xl? NXfvdJVvOTByIH7N MVS3NkBp MXTEUXNQ MlXQVoVi[3SrdnH0bY9vKG:oIF3lR5AzKG23dHHueEBmgHC{ZYPzbY9vKGG2IEGwJJRwKDFyMDDuUS=> NWXP[o1OOjF6NEC3NVY>
CFBE41o M4PnVGtqdmG|ZTDBd5NigQ>? MUC1JO69VQ>? M4fOemROW09? M4rWbmRwf25icnXneYxifGmxbjDv[kBJTEGFNzDheEAxNjJidH:gOUB2VQ>? MlPwNlE6QDR7NUi=
CFBE41o NUHXN5ZlTnWwY4Tpc44hSXO|YYm= MWKxJO69VQ>? MoXaNlQhcA>? NVzIOGhNTE2VTx?= NVj6eVdGWmW|dH;yZZRqd25ib3[gR2ZVWiCmZXz0ZWY2ODhibYX0ZY51KHS{YX\mbYNscW6pIITvJINmdGxic4Xy[oFk\SCjczDncJlkd2[xcn3z M3jvXVIyQTh2OUW4
DU145 M3m3c2tqdmG|ZTDBd5NigQ>? MnjqNk42KM7:TR?= NWWxN4ZqOjRiaB?= MVnEUXNQ M1HXT2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4YheDJzd3HmNUBxem:2ZXnuJIV5eHKnc4Ppc44> MX6yNlI3ODF4Nh?=
DU145 MnHjT4lv[XOnIFHzd4F6 M1SzdVUh|ryP MkPtNlQhcA>? NF:1dG5FVVOR MkTkTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGirc4TvcoUhUDRiYXPleJlt[XSrb36= MYOyNlI3ODF4Nh?=
DU145 MXnLbY5ie2ViQYPzZZk> M4DENlUh|ryP MmDRNlQhcA>? MWjEUXNQ NGTYdGtKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaHnzeI9v\SCKMzDofZBmemGlZYT5cIF1cW:w M{ThN|IzOjZyMU[2
786-0 M4K5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXq2MlIh|ryP M33TXVczKGh? MofHSG1UVw>? M1nuT2dKPTB;Mz6yJO69VQ>? NXTE[VRmOjJ2M{W2Olk>
A498 NEfpRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWi2MlIh|ryP NWWzT5lSPzJiaB?= MmDlSG1UVw>? NWrKcGtjT0l3ME2xMlYh|ryP MV:yNlQ{PTZ4OR?=
A549/ATCC NHfyOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HvTlYvOiEQvF2= MVK3NkBp M2TYemROW09? NHnUVWhIUTVyPUGuOkDPxE1? M{DWV|IzPDN3Nk[5
ACHN MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXm2MlIh|ryP MUm3NkBp NH\4R2JFVVOR M4fnW2dKPTB;MT6zJO69VQ>? M4njc|IzPDN3Nk[5
BT549 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH4UWI3NjJizszN MUe3NkBp MWLEUXNQ NYXMWmNrT0l3ME2xMlMh|ryP MmrINlI1OzV4Nkm=
EKVX NXr5XItHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv5Ok4zKM7:TR?= M2LWRVczKGh? NGjL[IZFVVOR MWjHTVUxRTFwMzFOwG0> MWeyNlQ{PTZ4OR?=
HCT15 NFPhZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVm2MlIh|ryP NWHrZXFvPzJiaB?= MULEUXNQ Mn70S2k2OD1{LkWg{txO MYSyNlQ{PTZ4OR?=
HOP92 NI\vXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fnZ|YvOiEQvF2= NHHtcWs4OiCq MX3EUXNQ M1\DXGdKPTB;NDFOwG0> MlG5NlI1OzV4Nkm=
IGROV1 M3PPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXjOXk3NjJizszN MmrmO|IhcA>? M13yb2ROW09? MXvHTVUxRTFwMzFOwG0> NYLNZ2hxOjJ2M{W2Olk>
LOXIMVI M{PxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jiUVYvOiEQvF2= M1nnbVczKGh? NXHuenFCTE2VTx?= M4Sw[WdKPTB;MTFOwG0> Mn\oNlI1OzV4Nkm=
M14 NUjlSXA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWK2MlIh|ryP MX[3NkBp M2Ly[2ROW09? MljNS2k2OD1zLkOg{txO NXizV|NIOjJ2M{W2Olk>
MALME-3M MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XLclYvOiEQvF2= Mn;6O|IhcA>? MlHRSG1UVw>? NVnhVHpmT0l3ME2wMlMzKM7:TR?= NUC3dZhjOjJ2M{W2Olk>
MCF10A Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfhSJg3NjJizszN Ml71OFghcA>? NX7wOW1KTE2VTx?= MnjjS2k2OD17Lk[g{txO NFn1VFIzOjR|NU[2PS=>
MDA-MB-435 NET2TZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;vbZc3NjJizszN NInvdIk4OiCq M{DQVGROW09? Mlf6S2k2OD1yLkWg{txO MX[yNlQ{PTZ4OR?=
MDA-MB-468 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rlWVYvOiEQvF2= M2DTWFczKGh? MVHEUXNQ NXPoSGpJT0l3ME2wMlY{KM7:TR?= NIn4WngzOjR|NU[2PS=>
MOLT4 MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nvUlYvOiEQvF2= MVK3NkBp NWfJbpJnTE2VTx?= MoD1S2k2OD1yLkSg{txO NWfScHZtOjJ2M{W2Olk>
NCI-ADR-RES M1PH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED1Zmw3NjJizszN NVjWT4ZrPzJiaB?= NHjDWoFFVVOR NIT1UlRIUTVyPUCuNVYh|ryP NVjGeGN4OjJ2M{W2Olk>
NCI-H23 NWnKeIU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\3N4Q{Pi5{IN88US=> MlS0O|IhcA>? Moe1SG1UVw>? NI\PPIVIUTVyPUGg{txO MkT5NlI1OzV4Nkm=
NCI-H322M M1rmRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:2MlIh|ryP NGPab3M4OiCq M1LVOmROW09? M1X6W2dKPTB;MD63PUDPxE1? M1y1S|IzPDN3Nk[5
NCI-H460 MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P3VFYvOiEQvF2= M1iwSlczKGh? MkKwSG1UVw>? NY\hcJhRT0l3ME2wMlc6KM7:TR?= MUSyNlQ{PTZ4OR?=
NCI-H522 NVvvbpZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVu2MlIh|ryP NYnYSnk5PzJiaB?= NXXuSHI2TE2VTx?= Ml;ES2k2OD1yLkWg{txO MX[yNlQ{PTZ4OR?=
OVCAR3 NEPO[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2noPFYvOiEQvF2= MWm3NkBp MVfEUXNQ MlfHS2k2OD1zLkOg{txO M1vqS|IzPDN3Nk[5
OVCAR4 M4H4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjnS5J3Pi5{IN88US=> NGXlUm84OiCq M3\Oe2ROW09? NFvJSYxIUTVyPUSg{txO M4fZNFIzPDN3Nk[5
OVCAR5 M3G0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXHVHpmPi5{IN88US=> MXK3NkBp MUfEUXNQ Mn:yS2k2OD1yLke5JO69VQ>? MWCyNlQ{PTZ4OR?=
OVCAR8 M4r0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr3b4pNPi5{IN88US=> M3zZbVczKGh? NVe1SpdxTE2VTx?= MXHHTVUxRTBwNTFOwG0> M33PTlIzPDN3Nk[5
RXF393 NV\D[JNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17PN|YvOiEQvF2= NWTiSmhuPzJiaB?= M3zTWWROW09? NH\FeYFIUTVyPUGuN{DPxE1? MnjnNlI1OzV4Nkm=
SF268 MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWm2MlIh|ryP MVS3NkBp NEjEUWxFVVOR MXnHTVUxRTFwNjFOwG0> MW[yNlQ{PTZ4OR?=
SF295 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\rcHA3NjJizszN M4LtfVczKGh? MmHtSG1UVw>? M3\ZN2dKPTB;MT62JO69VQ>? NYj3dVdSOjJ2M{W2Olk>
SF539 M3rJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvlOk4zKM7:TR?= NFP2dGg4OiCq M4r2fmROW09? MojPS2k2OD1{IN88US=> M4\0eFIzPDN3Nk[5
SK-MEL-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG4fYdIPi5{IN88US=> MV[3NkBp MmiwSG1UVw>? NIjhc5dIUTVyPUGuN{DPxE1? NVjzTFd1OjJ2M{W2Olk>
SK-MEL-28 M1zvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYW2MlIh|ryP MWe3NkBp NFvMU5hFVVOR M{XOVmdKPTB;MTFOwG0> NYO2Z3RYOjJ2M{W2Olk>
SK-MEL-5 MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPBOk4zKM7:TR?= NVyzcYt3PzJiaB?= M2H0[mROW09? NX;6Xo5[T0l3ME2wMlY{KM7:TR?= MorXNlI1OzV4Nkm=
SKOV3 NUnnNY1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV62MlIh|ryP NWP6e4VIPzJiaB?= MW\EUXNQ M1:3NWdKPTB;MTFOwG0> NWjrTWh4OjJ2M{W2Olk>
SN12C M2Lqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL1WFc3NjJizszN MYq3NkBp MnnUSG1UVw>? NF36XllIUTVyPUKg{txO NFvEcXYzOjR|NU[2PS=>
SNB19 NHzPUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\EWlYvOiEQvF2= NFrPeYI4OiCq NV\wZ4VtTE2VTx?= MoLTS2k2OD1yLk[zJO69VQ>? MkLjNlI1OzV4Nkm=
SNB75 NXLuWZhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVe2MlIh|ryP M1jHbFczKGh? NVvNUm1lTE2VTx?= NWXKOYRXT0l3ME2wMlc6KM7:TR?= NHq4bGozOjR|NU[2PS=>
SR NFXndIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TDNFYvOiEQvF2= MUm3NkBp NHTJdGFFVVOR NUjhR|FPT0l3ME2wMlQh|ryP M{KxeVIzPDN3Nk[5
T47D MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUi2MlIh|ryP NHnzN5g4OiCq M3ThZmROW09? MXXHTVUxRTBwNTFOwG0> M3PGfVIzPDN3Nk[5
TK10 M37TbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV62MlIh|ryP NIPXWIU4OiCq MULEUXNQ Mlu1S2k2OD1yLk[zJO69VQ>? MUGyNlQ{PTZ4OR?=
UACC257 NUD2[npTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7RUlk3NjJizszN MVK3NkBp MoHsSG1UVw>? Mmr2S2k2OD1yLkWg{txO NGfJU5kzOjR|NU[2PS=>
UACC62 M1jwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DwTlYvOiEQvF2= MVK3NkBp Moq3SG1UVw>? M1:5PWdKPTB;MD60JO69VQ>? NV7FV2ZkOjJ2M{W2Olk>
UO31 MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K4PVYvOiEQvF2= MXy3NkBp MYrEUXNQ MoCxS2k2OD1yLkWg{txO MonONlI1OzV4Nkm=
Hep3B NIDYVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUC0PEBp MlfySG1UVw>? NXTWOYhGT0l3ME2wMlY6KM7:TR?= MoXKNlI1Ozl6NkO=
BE(2)-C MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn5UnprPzJiaB?= Mn7tSG1UVw>? NEjqOXBKSzdyPUKg{txO MX2yNlk{OjNzNh?=
Bel7402 NWjycm5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDZV3k1PzJiaB?= MkTHSG1UVw>? MmSyS2k6OD1zNzFOwG0> NGTafXgzOzB4MUO3Oi=>
Bel7404 M2TiTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD5O|IhcA>? Moj2SG1UVw>? MVnHTVkxRTF6IN88US=> MV:yN|A3OTN5Nh?=
BGC823 NF\qdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXnO|IhcA>? NVuwdWVkTE2VTx?= M1nn[WdKQTB;Nz61JO69VQ>? M3XVdlI{ODZzM{e2
MGC803 MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWe3NkBp MoHYSG1UVw>? M1PUOWdKQTB;MUCuPEDPxE1? NYjIR49ZOjNyNkGzO|Y>
SGC7901 NGLQTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\KbXM4OiCq Moi3SG1UVw>? NHuxUZdIUTlyPUmuOEDPxE1? MWiyN|A3OTN5Nh?=
SKHEP1 NYPrZVhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\CO|IhcA>? NWSxbYJ6TE2VTx?= NUXXRZlNT0l7ME2xO{DPxE1? NYK3NW5GOjNyNkGzO|Y>
SMMC7721 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\4PVczKGh? NILVb2JFVVOR NGHvenFIUTlyPUKwJO69VQ>? MkG4NlMxPjF|N{[=
NUGC3 MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDqWWcyOCEQvF2= M1\HXWdKRTJwOUSg{txO M3PWelI{OTZ|M{Oy
A2780 CisR MV7LbY5ie2ViQYPzZZk> MmLJNVghcA>? NEfIOVVKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR|UxKG:oIECuOFQh|ryP M2q3OVI{OjV{NkCz
CAL27 sens Ml;TT4lv[XOnIFHzd4F6 NVLkdYhTOThiaB?= NVLi[oxJUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlM3KM7:TR?= NF\0TJozOzJ3Mk[wNy=>
CAL27 CisR MXTLbY5ie2ViQYPzZZk> NGLZem0yQCCq M2TM[GlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1? NEPqeXIzOzJ3Mk[wNy=>
KYSE-510 CisR Mlf1T4lv[XOnIFHzd4F6 MonmNVghcA>? MYHJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNUmg{txO MWCyN|I2OjZyMx?=
KYSE-510 sens NV7kfIg2U2mwYYPlJGF{e2G7 NUPpUoV3OThiaB?= MXnJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNzFOwG0> M1OzeVI{OjV{NkCz
MDA-MB-231 sens NXz1[XdzU2mwYYPlJGF{e2G7 M4TRXFE5KGh? NWnpUm5CUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlYyKM7:TR?= M3[zXlI{OjV{NkCz
MDA-MB-231 CisR NYXkTnBkU2mwYYPlJGF{e2G7 MmO0NVghcA>? M3jVUmlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1? Mln2NlMzPTJ4MEO=
ES2 M2LDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy5[4U1QCCq MoC2SG1UVw>? M4rFNGlEPTB;MUKuO{DPxE1? MV[yN|Q6OzR2OR?=
MDA-MB-231 Mo[yT4lv[XOnIFHzd4F6 NGWzUZIyOCEQvF2= M4TEXlMxKG2rbh?= Ml;HSG1UVw>? NWDXdZNIUW6qaXLpeIlwdiCxZjDISGFEOmF? M{TkWVI{PDl|NES5
MDA-MB-231 NVHlT3N2U2mwYYPlJGF{e2G7 MnnwNUDPxE1? NYTPcYRSOjRiaB?= NVn3ZYVwTE2VTx?= M3y1ZmlvcGmkaYTpc44hd2ZiSFTBR|Yh[XO|ZYPz[YQh[XNiYXPleJlt[XSrb36gcIV3\Wy|IH;mJJR2[nWuaX6= NH\re4czOzR7M{S0PS=>
HS68 NXjqdVU4S3m2b4TvfIlkKEG|c3H5 NIHIUGIyOCEQvF2= NGLj[444OiCq NELXTJhFVVOR M4rJN2lEPTB;ND62JO69VQ>? M4fTclI{PTdyNUSy
MEF NVjKTXlYS3m2b4TvfIlkKEG|c3H5 Mlq3NVAh|ryP NEHXb2E4OiCq NG\xR|ZFVVOR NYnubXpxUUN3ME20MlQh|ryP M3;4bFI{PTdyNUSy
BGC823 MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3roPWROW09? MXTHTVUxRTNwMEmg{txO M17odFI{PjBzN{C2
High5 MnvrT4lv[XOnIFHzd4F6 NF;4fIczPCCq NYHDTIRLUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEPiC5aYToJGlEPTBib3[gNE4xQSEQvF2= M4HTZlI{PjB{NUKz
High5 MlfxT4lv[XOnIFHzd4F6 NF7Jc4wzPCCq MYTJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOxJJdqfGhiSVO1NEBw\iByLkGyJO69VQ>? NIrhRZYzOzZyMkWyNy=>
High5 Mlf2T4lv[XOnIFHzd4F6 MV6yOEBp NY\QUohbUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEOyC5aYToJGlEPTBib3[gNE4yPyEQvF2= MlHXNlM3ODJ3MkO=
A549 M1v6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\PNnU3TE2VTx?= MX3JR|UxRTFwMEe5JO69VQ>? NIXWRYEzOzZ2NEKxNC=>
HCT116 M4rJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS5N2VFVVOR NFrhV|RKSzVyPUCuO|U4KM7:TR?= NWjWU4liOjN4NESyNVA>
K562 NWDKW492T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLEdFdFVVOR M{LscmlEPTB;MD62OFUh|ryP NX;G[FdJOjN4NESyNVA>
GBC-SD NHjK[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TNeFUh|ryP NHj0Nok4OiCq NVP2PJNKTE2VTx?= Ml\UTWM2OD1zND64JO69VQ>? NE\Kb2EzOzdyN{K2NC=>
HGC27 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2izbVUh|ryP NHXYTmk4OiCq MU\EUXNQ MlvwTWM2OD13LkSg{txO MWeyN|cxPzJ4MB?=
HL60 MmDtT4lv[XOnIFHzd4F6 NIPr[YE2KM7:TR?= MmnRNlQhcA>? M4rKdWROW09? NVHHRo9ZUW6qaXLpeIlwdiCxZjDISGFE MV2yN|cxPzJ4MB?=
Vero MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:3NkBp NYrP[FF2TE2VTx?= MWLJR|UxRTBwOTFOwG0> NEPEeo0zOzd6NkS1Ni=>
NCI60 MVHDfZRwfG:6aXOgRZN{[Xl? NHLDZWg1QCCq MoTDSG1UVw>? NE[3dYxIUT1yLkWzJO69VQ>? MnnoNlQxOTV|Mke=
SW620 NXLhR5BJS3m2b4TvfIlkKEG|c3H5 NFPadY01QCCq NI\hN2RFVVOR NITDNHdIUT1yLkW0JO69VQ>? NHLhVoMzPDBzNUOyOy=>
U251 M1n0TmN6fG:2b4jpZ{BCe3OjeR?= MmDXOFghcA>? MYnEUXNQ Mn\ES2k:OS53MzFOwG0> NXr0XZhMOjRyMUWzNlc>
KM12 MnjIR5l1d3SxeHnjJGF{e2G7 NGHnTII1QCCq M{Tq[GROW09? NInSWXlIUT1zLki4JO69VQ>? M{i2b|I1ODF3M{K3
Hs578T NXLLfHc6S3m2b4TvfIlkKEG|c3H5 MXq0PEBp MWXEUXNQ MmX0S2k:PC56MzFOwG0> NVnafo5VOjRyMUWzNlc>
MDA-MB-231 NGL6Rm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XCNFQ5KGh? NYPMd|l6UUN3ME2wMlE3KM7:TR?= NHjEOpQzPDB7NUCxOi=>
MCF7 NGjLcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrqcHY1QCCq M3S0bWdKRTBwNEWg{txO M{jTUVI1OTF7NUW1
MDA-MB-435 NULVVVVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL0XZA1QCCq Mlm5S2k:OC56ODFOwG0> M4HIO|I1OTF7NUW1
AsPC1 MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlriN|Ah|ryP MoHyOFghcA>? Mn;hSG1UVw>? MnzyTWM2OD1|Lk[2JO69VQ>? NGfBbnEzPDF6NUO3PC=>
Jurkat E6.1 NVPzcpFPU2mwYYPlJGF{e2G7 M{fLclIhcA>? NXfScpdjTE2VTx?= MU\Jcohq[mm2aX;uJI9nKEiGQVO0JJdqfGhiSVO1NEBw\iByLkC0JO69VQ>? MXmyOFI3OTh4Mh?=
KG1 MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX4VXdEPDhiaB?= NHvQOW1KSzVyPUGuNVUh|ryP NF;qRlIzPDV{NUCwNy=>
HEL M3jDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXW0WFBWPDhiaB?= M1;BTGROW09? M3G4PGlEPTB;MD60PUDPxE1? NF;pN3czPDZ7NEC1OS=>
HSC3 MXTDfZRwfG:6aXOgRZN{[Xl? MV:xNkBp NUPlVFFyTE2VTx?= M2LYNWlEPTB;MD63NUDPxE1? NGDjT5EzPDd4NkW2NC=>
HT-29 M4XPSGN6fG:2b4jpZ{BCe3OjeR?= M4HFZ|EzKGh? MlTrSG1UVw>? M120c2lEPTB;MD63NkDPxE1? MnX5NlQ4PjZ3NkC=
KB NWPGOpNvS3m2b4TvfIlkKEG|c3H5 MVexNkBp M1HBS2ROW09? NUm4dnl5UUN3ME2wMlc2KM7:TR?= MkXFNlQ4PjZ3NkC=
H460 NWjTfJZkS3m2b4TvfIlkKEG|c3H5 MXyxNkBp M3zIWGROW09? NU[3[m1oUUN3ME2wMlgzKM7:TR?= NHnYfoYzPDd4NkW2NC=>
MONE1 M1X0RmN6fG:2b4jpZ{BCe3OjeR?= Mo\NNVIhcA>? MnHZSG1UVw>? Ml;CTWM2OD1zLkG4JO69VQ>? NXvmOYJ{OjR5Nk[1OlA>
MKN45 NX7CSZRTS3m2b4TvfIlkKEG|c3H5 MVOxNkBp NXTnRWtCTE2VTx?= M4\4UmlEPTB;MT6yOUDPxE1? Mm\1NlQ4PjZ3NkC=
TSGH MkPGR5l1d3SxeHnjJGF{e2G7 MUGxNkBp MkPtSG1UVw>? MoD0TWM2OD1{LkC5JO69VQ>? NVfmc2hjOjR5Nk[1OlA>
HL60 M2jB[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWO3NkBp NWj3ZoNZTE2VTx?= NUXYVmc2T0l3ME2wMlk{KM7:TR?= NWrwOll3OjR7MEC1NFA>
HEK293 MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\lO|IhcA>? NWLGUFZuTE2VTx?= NF3DT4lIUTVyPUGzJO69VQ>? M4jHfFI1QTByNUCw
Jurkat NVvQPWtYS3m2b4TvfIlkKEG|c3H5 M3HMTVExOCEQvF2= MVi3NkBp M3SwUGdKPTB;MD65JO69VQ>? MViyOFkxODd2Mx?=
GM15850 M1fnZmtqdmG|ZTDBd5NigQ>? NYrNdHlEOi53IN88US=> NWfxbWV3QTZiaB?= NX;COVV7TE2VTx?= NVW1eWVO\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDNibInzbY5mKDF2IHHj[ZR6dGG2aX;uJI9nKE[[TjDn[Y5m MVqxOlkzOTN4Nx?=
GM15850 NEjWfJBMcW6jc3WgRZN{[Xl? M1\nOlIvPSEQvF2= MW[5OkBp Mme1SG1UVw>? Mnfl[I9meyCwb4SgbY5pcWKrdDDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm|aX7lJFUh[WOndInsZZRqd25ib3[gSnhPKGenbnW= NHvz[4wyPjl{MUO2Oy=>
GM15850 MmHmT4lv[XOnIFHzd4F6 MmTVNk42KM7:TR?= NVztems2QTZiaB?= MlzkSG1UVw>? NUfNeHBC\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDF{IHHj[ZR6dGG2aX;uJI9nKE[[TjDn[Y5m MojnNVY6OjF|Nke=
GM15850 NVu5bo4xU2mwYYPlJGF{e2G7 NFPUdHAzNjVizszN NHrKUWU6PiCq MUPEUXNQ NELT[nJld2W|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm|dH;u[UBJOyCueYPpcoUhQSCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=> MVWxOlkzOTN4Nx?=
GM15850 MYDLbY5ie2ViQYPzZZk> NY\lWVlkOi53IN88US=> NHWyXHg6PiCq NFO3TZRFVVOR NVTpS|dk\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDhiYXPleJlt[XSrb36gc4YhTliQIHflcoU> NX3FN|N3OTZ7MkGzOlc>
GM15850 M1vGc2tqdmG|ZTDBd5NigQ>? MUGyMlUh|ryP M2P5Slk3KGh? MonYSG1UVw>? NYfj[lIy\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDF4IHHj[ZR6dGG2aX;uJI9nKE[[TjDn[Y5m MVOxOlkzOTN4Nx?=
GM15850 NXP6c|U6TnWwY4Tpc44hSXO|YYm= MYq1JO69VQ>? NWC5fGVZOTJiaB?= NV72SYJpTE2VTx?= NGHXPG9p[XNibn:g[YZn\WO2IH;uJGZZViCvUl7BJIV5eHKnc4Ppc44> MYOxOlkzOTN4Nx?=
U937 M{m1[mtqdmG|ZTDBd5NigQ>? NH\vVVE2KM7:TR?= MkPjNlQhcA>? NWL3Z4ZUTE2VTx?= NEfwRplp[XNibn:g[YZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36= MUGxO|Q1Pzd3MB?=
U937 NWLLOmV1U2mwYYPlJGF{e2G7 NXjE[ZVGOSEQvF2= MmTPNlQhcA>? MnPuSG1UVw>? NECzbotp[XNibn:g[YZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36= NV3GUlc5OTd2NEe3OVA>
PANC1 MlzTSpVv[3Srb36gRZN{[Xl? M3rMflEh|ryP NX3TbFJnOjRiaB?= NX\lTZB7\G:nczDuc5QhcW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44> MWixO|U5QDd2NB?=
PANC1 MW\GeY5kfGmxbjDBd5NigQ>? NWrwUI45OSEQvF2= NEX5VWM1QCBiaB?= NEPpR5Vld2W|IH7veEBqdmO{ZXHz[UBqdiCyMkfrbZAyKGenbnWg[ZhxemW|c3nvci=> NHHCWnEyPzV6OEe0OC=>
Caco-2 MkH2SpVv[3Srb36gRZN{[Xl? M1i0dVUh|ryP M{TxOlI1KGh? NWPCcFhWTE2VTx?= MXHkc4V{KG6xdDDpcoR2[2ViUEKxW2FHOSCpZX7lJIV5eHKnc4Ppc44> NHfIZZczODF2M{i0NC=>
SCC4 MXLGeY5kfGmxbjDBd5NigQ>? M1XF[FEh|ryP NWT0bpFtOTBibXnu NYrpOXJlTE2VTx?= M3\j[4hieyCwbzDh[49vcXO2IHHjeIl3cXS7IHH0JHZFWiCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhS1mSMkSg[4Vv\SCneIDy[ZN{cW:w NWCzd2pEOjB2NUKyNlU>
A549 NITRTFZHfW6ldHnvckBCe3OjeR?= NXzNfHRYPSEQvF2= M3nGXlMhcA>? NH\O[4hFVVOR NGPlU2Vld2W|IH7veEBqdmS3Y3WgZZV1d3CqYXf5JIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIFzDN2lK NWfIU3hQOjB6NUWyNFg>
HCT116 M4q2VmtqdmG|ZTDBd5NigQ>? MnjsNE4{KM7:TR?= NYXrOZQ2OzBiaB?= M3fUTWROW09? MlW0[I9meyCwb4SgbY5pcWKrdDDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm|dH;u[UBJO0t7IHHj[ZR6dGG2aX;u NVvZPFN5OjFyOEC2OFc>
HepG2 NH\kfmtHfW6ldHnvckBCe3OjeR?= Mk\ZNVAh|ryP NXfkWJhyOjRiaB?= MnPVSG1UVw>? M1L3doRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhcHmyZYLhZ4V1gWyjdHnvckBw\iCyNUO= NGOzR5kzOTV2OEW4Ni=>
GM11272 NXfKXFFnTnWwY4Tpc44hSXO|YYm= MWWwMlEh|ryP NWLPcIpjPzJiaB?= MmjWSG1UVw>? NELS[FVld2W|IH7veEBz\WGldHn2ZZRmKE2nQ4CyJI12fGGwdDDlfJBz\XO|aX;u M1LoTVIyQDRyN{G2
MDA-MB-231 NIC2elZMcW6jc3WgRZN{[Xl? MlXnNVAh|ryP M2rjTFUhdWmw M{LUcWROW09? NVT0OJBP\G:nczDuc5QhcW6qaXLpeEBJTEGFMnG= MmfENlM1QTN2NEm=
MDA-MB-231 NHzsO2NMcW6jc3WgRZN{[Xl? M2nWfFEh|ryP M3yyXVI1KGh? Mnv0SG1UVw>? MmPQ[I9meyCwb4SgbY5pcWKrdDDISGFEPiCjc4Pld5Nm\CCjczDhZ4V1gWyjdHnvckBt\X[nbIOgc4YhfHWkdXzpci=> M3\NcFI{PDl|NES5
K562 NWfUVJVUU2mwYYPlJGF{e2G7 NVHWfG5{\G:nczDuc5QhcW6qaXLpeEBJTEGF Mo\XNlM2QTFzMUG=
Jurkat NXLjNJpqS3m2b4TvfIlkKEG|c3H5 M1LHNFIxKM7:TR?= NIjBbJU4OiCq NWHDU2VGTE2VTx?= MXruc{BkgXSxdH;4bYNqfHliYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36= MYOyOFMxPDN2OB?=
HCT116 MVfBdI9xfG:|aYOgRZN{[Xl? NF:wfGc{KM7:TR?= MU[yOEBp NYfBSllETE2VTx?= NWnnbVdI\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwOVMheHKxdHXpckBt\X[nbB?= M{W0UFI1PzZ4NU[w
KASUMI-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTzTZFmUUN3ME25PU4yPyCwTR?= MnfBV2FPT0WU
KARPAS-45 M1Kx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M160dWlEPTB;MUezMlg6KG6P MVLTRW5ITVJ?
BHT-101 M1Xx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH33NnVKSzVyPUK0OE4yQCCwTR?= MXnTRW5ITVJ?
H9 MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fsUGlEPTB;MkW1MlA1KG6P NE\0WlZUSU6JRWK=
PA-1 M2\nPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHvN2hKSzVyPUK4Ok4zPiCwTR?= M4[5SnNCVkeHUh?=
NEC8 NEP6T5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTFTWM2OD1{OEmuN|ghdk1? M{KwUnNCVkeHUh?=
MHH-PREB-1 M{LBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJ7ND61N{BvVQ>? NUfWc4pRW0GQR1XS
NB7 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjQRXJKSzVyPUO0OU44PCCwTR?= NYj2eYx4W0GQR1XS
A3-KAW MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NImwdG5KSzVyPUSwNE42QSCwTR?= NEja[YtUSU6JRWK=
NB69 MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nDTWlEPTB;NEGxMlcyKG6P M2LPd3NCVkeHUh?=
EoL-1-cell MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH6zZ5NKSzVyPUS1OFI2KG6P M3HrWHNCVkeHUh?=
CHP-212 NITNRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDXTWM2OD12NUeuOVMhdk1? M17SeXNCVkeHUh?=
C2BBe1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTR5Mj6xPUBvVQ>? NYrYWWRFW0GQR1XS
697 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HWe2lEPTB;NEezMlQyKG6P M4DBUXNCVkeHUh?=
BCPAP M3HkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDrWXZnUUN3ME21NFEvPDJibl2= MVfTRW5ITVJ?
L-363 MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTVyMz6xJI5O M3;J[nNCVkeHUh?=
ES8 NV;rVGJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTV{Mz61N{BvVQ>? M2\OWXNCVkeHUh?=
BE-13 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfmVotKSzVyPUWyOk46PiCwTR?= NH31fllUSU6JRWK=
CTB-1 NIm2TVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz3TWM2OD13M{euPVIhdk1? MmXrV2FPT0WU
HD-MY-Z MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTyRW1KSzVyPUWzPE4yOyCwTR?= NXLyVXZ5W0GQR1XS
NKM-1 NWDvT2h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPBRYZKSzVyPUW0OE4zPyCwTR?= NW[y[3FbW0GQR1XS
NCI-H720 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHFZ|lUUUN3ME21OlAvOThibl2= MUPTRW5ITVJ?
KY821 MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTV4Mz6yOUBvVQ>? NEftW|JUSU6JRWK=
OVCAR-5 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTV5Nj6xNUBvVQ>? M4jjPXNCVkeHUh?=
CTV-1 NH;YOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTV6MT61OkBvVQ>? MWTTRW5ITVJ?
P12-ICHIKAWA NF7rfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;6TWM2OD13OU[uOVEhdk1? M2TEOnNCVkeHUh?=
DB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL5TWM2OD13OUiuOVchdk1? MVTTRW5ITVJ?
CHL-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPsSIJIUUN3ME22OFIvODhibl2= MlzoV2FPT0WU
A4-Fuk Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXIXFRKSzVyPU[0OE46OSCwTR?= MXXTRW5ITVJ?
MV-4-11 MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTZ3OT6xJI5O NFvQSllUSU6JRWK=
RPMI-8226 M1HZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LzdGlEPTB;Nke4MlE5KG6P MoC4V2FPT0WU
NB14 NEPIT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PmdWlEPTB;Nkm2Mlk2KG6P NWWwZo1YW0GQR1XS
DOHH-2 M2HDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrCTWM2OD15ME[uOlghdk1? NVXWfI9nW0GQR1XS
D-423MG NGDPUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmntTWM2OD15ME[uPFkhdk1? NIroWYpUSU6JRWK=
D-283MED NVXZW4dzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi4d24yUUN3ME23NVQvOTRibl2= M{\3O3NCVkeHUh?=
ES1 NGTCVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrXdJdnUUN3ME23NlQvPCCwTR?= M1H1dXNCVkeHUh?=
GOTO NI\QNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonVTWM2OD15MkmuNVIhdk1? M4f1fHNCVkeHUh?=
NCI-H209 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrzTVRKSzVyPUeyPU46KG6P MoHuV2FPT0WU
MOLT-13 NUjs[|NsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e2TWlEPTB;N{O4Mlk5KG6P Ml\DV2FPT0WU
ATN-1 NIT6SXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTiTWM2OD15NECuNlghdk1? MX7TRW5ITVJ?
DU-4475 NGLqWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTd3MT65NUBvVQ>? M{PKfXNCVkeHUh?=
NB10 NUG2UFY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y3NGlEPTB;N{WxMlkzKG6P NXfTenJGW0GQR1XS
KG-1 NVvsXoJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr4WmlKSzVyPUe3OU41PSCwTR?= NUG3dZY6W0GQR1XS
MOLT-4 M3LhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXLTWM2OD15OEeuOFYhdk1? NGe0eIVUSU6JRWK=
TE-1 NXXm[YNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTd7MT6xJI5O M1HTWXNCVkeHUh?=
SBC-1 M1[0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTd7Mz64OEBvVQ>? NHzz[nBUSU6JRWK=
HEL MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRThyNj6wPEBvVQ>? NYCzWotCW0GQR1XS
SK-MEL-2 M4G2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\sT2lEPTB;OEC5MlQ1KG6P NUnPeWdmW0GQR1XS
KU812 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\3Tm1KSzVyPUixN{4yKG6P NYC3XGhXW0GQR1XS
RPMI-8866 NW[5bG9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TxdGlEPTB;OEGzMlY4KG6P MmXKV2FPT0WU
ALL-PO NFW3dGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrO[4hKSzVyPUixOE43PiCwTR?= MkGzV2FPT0WU
LU-139 NWPrdFR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF73eZVKSzVyPUiyNk45PiCwTR?= MYnTRW5ITVJ?
RS4-11 NF\mUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTh|Mj60OUBvVQ>? NITMT4RUSU6JRWK=
EW-18 NHnoVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjZ[JNpUUN3ME24N|IvQTZibl2= MlPUV2FPT0WU
P30-OHK MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnSU5JKSzVyPUizOU44KG6P NH7k[GNUSU6JRWK=
D-566MG NU\POWI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjWTWM2OD16M{iuOlIhdk1? M3TYWnNCVkeHUh?=
HSC-4 NFrJbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTCPIN6UUN3ME24OFYvPTFibl2= M2fzT3NCVkeHUh?=
QIMR-WIL MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH6z[mJKSzVyPUi2Nk4xOyCwTR?= MV3TRW5ITVJ?
SW954 M2XQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPkTWM2OD16NkOuNVYhdk1? NWrnU4t6W0GQR1XS
HGC-27 NFfsZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PkWWlEPTB;OEeyMlM1KG6P MoTIV2FPT0WU
HH NVyxXZNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLQTWM2OD16OUSuNVIhdk1? NXrKNmZTW0GQR1XS
KE-37 MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTSe3NKSzVyPUi5OE43OiCwTR?= NYTuNmo4W0GQR1XS
SK-N-DZ NFPw[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTlyMD60N{BvVQ>? M1rR[nNCVkeHUh?=
J-RT3-T3-5 MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LKdGlEPTB;OUGwMlQ6KG6P MXnTRW5ITVJ?
A427 MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LhWmlEPTB;OUKwMlg1KG6P MlTxV2FPT0WU
ECC10 M1vCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTl2NT64O{BvVQ>? MYrTRW5ITVJ?
EW-1 NYnBcJhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULPWXZmUUN3ME25OFcvOjZibl2= NUK1fFg4W0GQR1XS
MIA-PaCa-2 MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfDTWM2OD17NEmuNVIhdk1? NGfjPZVUSU6JRWK=
HCC2218 NIjMN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTl3OD60PEBvVQ>? NIW2NohUSU6JRWK=
HAL-01 NF3tWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PQfWlEPTB;OU[4MlA1KG6P NEHafIdUSU6JRWK=
RD M3vpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTl5ND60OUBvVQ>? NGLRe49USU6JRWK=
SK-N-AS MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTl6OD6xJI5O MlvYV2FPT0WU
ML-2 Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjXRVM6UUN3ME2xMlAxPDB5IN88US=> MnrZV2FPT0WU
MEL-HO NWPvdolPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HqR2lEPTB;MT6wNFU5OiEQvF2= NHHDeFRUSU6JRWK=
MS-1 M4KzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13RV2lEPTB;MT6wNFYyPyEQvF2= M{i3enNCVkeHUh?=
NCI-SNU-1 NHrJcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH4TWM2OD1zLkCyN|MyKM7:TR?= MVzTRW5ITVJ?
8505C MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fCN2lEPTB;MT6wNlM{OSEQvF2= NGHQUGJUSU6JRWK=
MN-60 NF\jVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr1TWM2OD1zLkCyOlgh|ryP M4q2O3NCVkeHUh?=
SAS NHPVeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwMESwPFEh|ryP M3HaN3NCVkeHUh?=
EFM-19 NYO3d5BjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLwTWM2OD1zLkC0PFc6KM7:TR?= MX3TRW5ITVJ?
Ca9-22 MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rwO2lEPTB;MT6wOVExPyEQvF2= Mmj0V2FPT0WU
NBsusSR MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPJUYZKSzVyPUGuNFUyPjZizszN M4e4T3NCVkeHUh?=
NB13 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFwMEW1NFEh|ryP NES4UVZUSU6JRWK=
SF295 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwME[2NlQh|ryP M3jJNnNCVkeHUh?=
U-2-OS MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjuNmxyUUN3ME2xMlA4QTFzIN88US=> MWjTRW5ITVJ?
NCI-H526 M3Ti[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vrd2lEPTB;MT6wPFI6OSEQvF2= NVfNOG9TW0GQR1XS
KMOE-2 M{f0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHlXY57UUN3ME2xMlA6PDJ{IN88US=> NUS0fGtVW0GQR1XS
RCM-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uwPWlEPTB;MT6xNlExOiEQvF2= MWDTRW5ITVJ?
MC116 NIHweIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7abGNKSzVyPUGuNVM3OjFizszN M1fWWXNCVkeHUh?=
NCI-H1092 NGq1WFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7HTWM2OD1zLkG1OFA3KM7:TR?= M4\VSnNCVkeHUh?=
EW-3 NVvGeVl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDpPItKSzVyPUGuNVczOTJizszN M3LvSHNCVkeHUh?=
HCT-116 NGnEWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHZOoRJUUN3ME2xMlE4PzVizszN MVPTRW5ITVJ?
MC-IXC NXu2dmE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwMUe4PFEh|ryP NYnJe21NW0GQR1XS
LB1047-RCC NHHCWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13oN2lEPTB;MT6xPFMyOiEQvF2= M3f5W3NCVkeHUh?=
VM-CUB-1 MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrnTFlKSzVyPUGuNVkyODhizszN MYDTRW5ITVJ?
NB5 NYO3SVV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwMUm4OVYh|ryP NXfjNWtuW0GQR1XS
SKG-IIIa MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\1TWM2OD1zLkKzOFY1KM7:TR?= M{Hnc3NCVkeHUh?=
HO-1-N-1 M1\WR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTITWM2OD1zLkKzPFM2KM7:TR?= MkHEV2FPT0WU
EFO-27 NFG1bXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFwMkWwOFMh|ryP MnTmV2FPT0WU
MHH-NB-11 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f0UmlEPTB;MT6yPFMzQSEQvF2= MUDTRW5ITVJ?
SW620 M3myVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXOTWM2OD1zLkK5NFE5KM7:TR?= MUXTRW5ITVJ?
MOLT-16 NGLNVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPaR3ZbUUN3ME2xMlI6Pzl5IN88US=> Ml7DV2FPT0WU
NTERA-S-cl-D1 NFHNSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7qTWM2OD1zLkOxO|YyKM7:TR?= NFWzNXZUSU6JRWK=
VA-ES-BJ M2PFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFwM{K0O|ch|ryP MV7TRW5ITVJ?
HCC1419 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPtTWM2OD1zLkO0NFI4KM7:TR?= NGrmWoxUSU6JRWK=
NCI-H69 MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4qyfmlEPTB;MT6zOFEyOiEQvF2= MULTRW5ITVJ?
DEL NIXQO|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;sUmlEPTB;MT6zOVE3OiEQvF2= MUHTRW5ITVJ?
LXF-289 MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDkOYlKSzVyPUGuN|UzPCEQvF2= NFPOSJpUSU6JRWK=
EW-11 MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD1TWM2OD1zLkO2NFI3KM7:TR?= M2jFPXNCVkeHUh?=
KP-4 M2fpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\z[nlKSzVyPUGuN|cxQDVizszN NWXQ[JVNW0GQR1XS
NOS-1 MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFwNEGxPVQh|ryP MX3TRW5ITVJ?
SK-NEP-1 Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzQTWM2OD1zLkSxOlk{KM7:TR?= MYTTRW5ITVJ?
LAMA-84 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFwNEO5OFUh|ryP MXrTRW5ITVJ?
ES5 NWixVXhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFwNESzJO69VQ>? MV7TRW5ITVJ?
HuO9 Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFwNEWzOlIh|ryP NXvEcWdnW0GQR1XS
COLO-684 NEnhcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUGwfYVtUUN3ME2xMlQ3OTF6IN88US=> NIq4NHRUSU6JRWK=
EW-24 NHHrSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFwNE[1N|Eh|ryP NGPE[HVUSU6JRWK=
BV-173 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG4TWM2OD1zLkS3NlkyKM7:TR?= NWXBb2ZjW0GQR1XS
NCI-H1770 NWrDTppjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\vTJpWUUN3ME2xMlQ5PTN4IN88US=> M3Hz[XNCVkeHUh?=
HuP-T4 MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFwNEmzJO69VQ>? MonJV2FPT0WU
TYK-nu M4DZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Hj[2lEPTB;MT60PVg2OSEQvF2= NVH2RpU{W0GQR1XS
YH-13 M3XMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjpeWpKSzVyPUGuOFk5QTRizszN NH7SNlFUSU6JRWK=
H4 M33LOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\UfJhqUUN3ME2xMlUxQTF{IN88US=> NIftTVdUSU6JRWK=
OVCAR-8 M{T0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jXU2lEPTB;MT61OFQ4PyEQvF2= NFjXXlFUSU6JRWK=
NCI-H23 M4Xsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrl[2tKSzVyPUGuOVQ3PDVizszN NHHSbHBUSU6JRWK=
ES7 M2HrVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPyOGVkUUN3ME2xMlU1Pzd|IN88US=> NUfRR2dRW0GQR1XS
COR-L88 M1G1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFwNU[0NlQh|ryP NEnqXZlUSU6JRWK=
TI-73 NUfHfZg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwNUmwOkDPxE1? NFLZN3dUSU6JRWK=
RT-112 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFwNUmyPFQh|ryP M3jVc3NCVkeHUh?=
HuO-3N1 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFwNUmzPFUh|ryP NGS2[m9USU6JRWK=
HC-1 M4HDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFwNUm4OlYh|ryP NF:3cGNUSU6JRWK=
HT55 NG\wO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFwNkWxN|Eh|ryP NGLOb4RUSU6JRWK=
IA-LM MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfrZZBKSzVyPUGuOlkzPzhizszN NUXhfYNEW0GQR1XS
EM-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjjbI9KSzVyPUGuO|AxOTRizszN MX3TRW5ITVJ?
MHH-ES-1 NH:0dIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYKz[o1pUUN3ME2xMlcxPDN3IN88US=> NYnGbGVUW0GQR1XS
CAL-27 Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnpO2xUUUN3ME2xMlcxPjJzIN88US=> M3Xx[XNCVkeHUh?=
COLO-800 NWnVUnZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvQPFJKSzVyPUGuO|EyPzlizszN MVXTRW5ITVJ?
HCE-T M33GVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:0RVlKSzVyPUGuO|E2KM7:TR?= NFTWWZVUSU6JRWK=
CAMA-1 NHnFVYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDnTWM2OD1zLkexPVcyKM7:TR?= NHHZO|lUSU6JRWK=
LOXIMVI NFzKd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoKwTWM2OD1zLkeyNVEh|ryP NFzsUHFUSU6JRWK=
NH-12 NWnYb3M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLLVJRKSzVyPUGuO|I3QTFizszN M3XtS3NCVkeHUh?=
TCCSUP MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3hTplrUUN3ME2xMlczQDJ7IN88US=> M{TvT3NCVkeHUh?=
MDA-MB-361 M3:wTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfjWY52UUN3ME2xMlc{OTV5IN88US=> MlX2V2FPT0WU
EW-16 NFyxfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFwN{SxNFch|ryP M4TFcHNCVkeHUh?=
SNU-423 MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\FboVKSzVyPUGuO|U5OjdizszN MXvTRW5ITVJ?
Daoy NUL4R3NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2K4VGlEPTB;MT63OlMyQSEQvF2= M1nlNXNCVkeHUh?=
ES4 M{jqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYm5TlZMUUN3ME2xMlc5PzRzIN88US=> M2C2VHNCVkeHUh?=
PFSK-1 MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17vZmlEPTB;MT64NFM4KM7:TR?= NYPTd4xxW0GQR1XS
ES3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnzb|J2UUN3ME2xMlgzPjhzIN88US=> NWfWXHNVW0GQR1XS
ONS-76 NEHZWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7ZTXdKSzVyPUGuPFI5QTdizszN M{XrVnNCVkeHUh?=
JVM-3 NXezboIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwOEW0OVEh|ryP NWfme|FGW0GQR1XS
OS-RC-2 NE\QbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYryUIxkUUN3ME2xMlg4OTVzIN88US=> M4DhWnNCVkeHUh?=
COLO-320-HSR NYTWPIZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmKzTWM2OD1zLki4NVk4KM7:TR?= MmLLV2FPT0WU
HN MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\PUmlEPTB;MT64PFczPSEQvF2= MUjTRW5ITVJ?
HT NWDZNVdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrvTWM2OD1zLki4PVQ4KM7:TR?= M3LGbHNCVkeHUh?=
LoVo NGSzO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nufmlEPTB;MT64PVgyKM7:TR?= M3y2UnNCVkeHUh?=
CGTH-W-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjzWXNpUUN3ME2xMlg6QTR4IN88US=> M{ftNHNCVkeHUh?=
NB6 NU\v[3JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUOxW2RHUUN3ME2xMlkyOjl6IN88US=> NHv3UpZUSU6JRWK=
EW-22 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILjS|NKSzVyPUGuPVI5QDdizszN Mme3V2FPT0WU
ES6 NFXXUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXwTWM2OD1zLkmzOlMyKM7:TR?= Mm\SV2FPT0WU
SCC-15 NH[yXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle5TWM2OD1zLkmzPFE6KM7:TR?= M1;hdnNCVkeHUh?=
HL-60 NVH1[|VXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLBTWM2OD1zLkmzPVAzKM7:TR?= NHvQdo9USU6JRWK=
human HOP-92 M2XXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\4Xo1NUUN3ME2xMlk1ODZ3IN88US=> NFW0OpZUSU6JRWK=
SW626 NXjIVHQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn4V5FKSzVyPUGuPVQ5QTlizszN NYDzSpJyW0GQR1XS
HEC-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H2Z2lEPTB;MT65OVM3KM7:TR?= MXXTRW5ITVJ?
LB2241-RCC MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrrNVFKUUN3ME2xMlk5OjNzIN88US=> MYTTRW5ITVJ?
Ramos-2G6-4C10 NGfFV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjZTWM2OD1zLkm5OFk{KM7:TR?= NGnrWGhUSU6JRWK=
A101D MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJwMkCzNFMh|ryP M4XIZnNCVkeHUh?=
NCI-H446 NY\DT4l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7RcWlKSzVyPUKuNFQ2QTlizszN MWLTRW5ITVJ?
SBC-5 NIrTW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3DTWM2OD1{LkC2NVQ4KM7:TR?= NW[x[2hJW0GQR1XS
HOS M2DReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJwMEe2OVMh|ryP Mof6V2FPT0WU
K5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\FWmQ{UUN3ME2yMlA4QDFzIN88US=> NU\rXFllW0GQR1XS
HLE NHn5d|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljVTWM2OD1{LkC4OVI6KM7:TR?= M3LuTXNCVkeHUh?=
HSC-2 M2rmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe3cVBQUUN3ME2yMlEzQDl6IN88US=> NYHI[2dXW0GQR1XS
LCLC-97TM1 MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\NdnIyUUN3ME2yMlE1PTh|IN88US=> NG\J[VNUSU6JRWK=
DMS-273 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;SOWlEPTB;Mj6xOFg{PyEQvF2= M1njSHNCVkeHUh?=
TE-8 M1zzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJwMUW3OlUh|ryP NHLrfVdUSU6JRWK=
DSH1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rq[mlEPTB;Mj6xOlM6QCEQvF2= M4O0THNCVkeHUh?=
CAL-51 M2T2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorzTWM2OD1{LkG2Olk6KM7:TR?= Ml\RV2FPT0WU
IST-SL1 NWHQZpJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLvTWM2OD1{LkG2PFQ1KM7:TR?= MlLhV2FPT0WU
GCT MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv4TWM2OD1{LkG3O|ch|ryP Ml\DV2FPT0WU
SW948 NFXoNnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfWXJZYUUN3ME2yMlE5PDV4IN88US=> MVPTRW5ITVJ?
NOMO-1 Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX0fnBKSzVyPUKuNVk{OTdizszN MlzoV2FPT0WU
C8166 NHrDSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfucppjUUN3ME2yMlIyOzN2IN88US=> NVzKTHpbW0GQR1XS
OC-314 M2Xre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYWyS|JVUUN3ME2yMlI{OjV7IN88US=> M4LpNnNCVkeHUh?=
CAL-39 NGWzVnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKxW|dKSzVyPUKuNlM3OjZizszN M33IdHNCVkeHUh?=
MDA-MB-453 M1XydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L1OGlEPTB;Mj6yOFI4PSEQvF2= NXniVFhCW0GQR1XS
A673 NVHyZ29CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fVbGlEPTB;Mj6yOVg3OiEQvF2= M2HWfnNCVkeHUh?=
HTC-C3 NWP3XWtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDnOphEUUN3ME2yMlI3QDVizszN M1\5NnNCVkeHUh?=
NCI-H1666 M3H3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJwMkixNVEh|ryP M2nQ[nNCVkeHUh?=
PSN1 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnFbG1EUUN3ME2yMlI5QTF|IN88US=> MmfSV2FPT0WU
GI-1 NX3NZpdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3XOFhyUUN3ME2yMlMxPTR|IN88US=> MmXDV2FPT0WU
HuH-7 MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jtd2lEPTB;Mj6zNFY{PyEQvF2= MWPTRW5ITVJ?
JAR NWraepJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJwM{G5PFch|ryP NHL4ZnFUSU6JRWK=
5637 NFztSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJwM{KxNlkh|ryP MXHTRW5ITVJ?
GB-1 M1L2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXIW3BGUUN3ME2yMlMzOzN3IN88US=> NWnSW5UyW0GQR1XS
KP-N-YS MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPG[4pKSzVyPUKuN|I3OTVizszN NUe1WFVyW0GQR1XS
OAW-42 NXn2d21DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEK3eVNKSzVyPUKuN|M1OTZizszN NHfCeYRUSU6JRWK=
8-MG-BA NH\EflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jyWGlEPTB;Mj6zN|kxPiEQvF2= NFfZ[XNUSU6JRWK=
RH-18 MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJwM{WwNlIh|ryP NIG3U4NUSU6JRWK=
NCI-H1155 NF\GVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDJRnRKSzVyPUKuN|Y4OjVizszN NIXTcYZUSU6JRWK=
NB17 MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj3WFUzUUN3ME2yMlM5OjR|IN88US=> M1joV3NCVkeHUh?=
NCI-H1437 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\zTWM2OD1{LkSxPFc{KM7:TR?= NFH3dZlUSU6JRWK=
SN12C M2TSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\XZYppUUN3ME2yMlQ{OjF2IN88US=> NUjVZ|lDW0GQR1XS
HSC-3 MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHVV2s5UUN3ME2yMlQ1PTB7IN88US=> NHTqc|hUSU6JRWK=
GAMG NGOyZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPITWM2OD1{LkS0OVYyKM7:TR?= MnHmV2FPT0WU
HT-1080 NVzrbI5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTaTXI2UUN3ME2yMlQ1QDZ2IN88US=> MW\TRW5ITVJ?
A549 NIe5fGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTxem03UUN3ME2yMlQ1QDl|IN88US=> MXTTRW5ITVJ?
KNS-62 M3K1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTnTWM2OD1{LkS1NFYyKM7:TR?= NEjNXo1USU6JRWK=
YKG-1 NX7BSYdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPDTmY{UUN3ME2yMlQ2PDN5IN88US=> M2LWPHNCVkeHUh?=
LU-134-A NX31N3prT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rkc2lEPTB;Mj60O|AxQCEQvF2= MWLTRW5ITVJ?
FADU NUHtZlFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\qW2lEPTB;Mj60O|E3OiEQvF2= NISxNJVUSU6JRWK=
TGBC11TKB NVjITJRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPGTWM2OD1{LkS3NVc4KM7:TR?= MX7TRW5ITVJ?
HT-3 NFW4W5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPUfVhXUUN3ME2yMlQ6PTN3IN88US=> MVPTRW5ITVJ?
NCI-H2170 NIfKNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT1XWlKSzVyPUKuOVA2PDlizszN MmfDV2FPT0WU
Mo-T NIPGSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDBTIhKSzVyPUKuOVA6OjdizszN M{SzV3NCVkeHUh?=
CCRF-CEM M2HHWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrTU|dKSzVyPUKuOVMxPDNizszN MlLKV2FPT0WU
KU-19-19 NHSzOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDY[YFIUUN3ME2yMlU{PTF|IN88US=> MWHTRW5ITVJ?
NCI-H1048 NVrEUHgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XneGlEPTB;Mj61OVAzPSEQvF2= NXLkVYJ6W0GQR1XS
KOSC-2 NUD2Z2l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLzTWM2OD1{LkW2NFc3KM7:TR?= NVXCZ5FKW0GQR1XS
A431 NUK0dmR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7iN3BKSzVyPUKuOVY{OzVizszN NHzNS3BUSU6JRWK=
COR-L23 M3\oS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJwNUi1OlYh|ryP M{nOXHNCVkeHUh?=
MKN28 M1rsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJwNUmwN|ch|ryP MYXTRW5ITVJ?
22RV1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfJXoNSUUN3ME2yMlU6Ojd2IN88US=> MorUV2FPT0WU
ABC-1 NVfOWpNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TvTGlEPTB;Mj62NFQ3KM7:TR?= MmOzV2FPT0WU
NCI-H2126 MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq0c5ZKSzVyPUKuOlA6QDRizszN M4XL[HNCVkeHUh?=
DoTc2-4510 M2DmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP6[oVKSzVyPUKuOlIyQDVizszN MVXTRW5ITVJ?
SCC-4 MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f1OGlEPTB;Mj62N|AyOiEQvF2= NXvqVXRiW0GQR1XS
NCI-H661 NIfSWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJwNkSwPFUh|ryP NVvEZVZzW0GQR1XS
RPMI-2650 NX7VdYl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS1[lVDUUN3ME2yMlY1OTR|IN88US=> M4DCXHNCVkeHUh?=
NCI-H510A M1jsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJwNkS0NlYh|ryP NX3FZlNUW0GQR1XS
BPH-1 M{LYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXETWM2OD1{Lk[1PFUh|ryP MVzTRW5ITVJ?
M14 NEL2XVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm1TWM2OD1{Lk[2PVk{KM7:TR?= NEPYZ4dUSU6JRWK=
G-402 M32xXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfycJVZUUN3ME2yMlcxPDVzIN88US=> MVLTRW5ITVJ?
AsPC-1 Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnh[4JRUUN3ME2yMlcyOTdizszN MVzTRW5ITVJ?
NB12 NFO1SFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJwN{G3NUDPxE1? MmT0V2FPT0WU
SK-HEP-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJwN{SzPVEh|ryP NYPOZpA6W0GQR1XS
U-266 NVnD[VlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\r[mlEPTB;Mj63O|EzOSEQvF2= MULTRW5ITVJ?
AM-38 NXHiZ4h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P2b2lEPTB;Mj63O|M2PSEQvF2= NFj3SFZUSU6JRWK=
PC-14 NIrHPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jnNWlEPTB;Mj64NFUyKM7:TR?= NYnaTZBFW0GQR1XS
EGI-1 NFX5dnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nMUWlEPTB;Mj64NVc1OyEQvF2= M4H0enNCVkeHUh?=
LS-411N MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6zcJRKSzVyPUKuPFI{OyEQvF2= NWj3WGRQW0GQR1XS
BFTC-905 Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHoTWM2OD1{Lki1OVI{KM7:TR?= MX7TRW5ITVJ?
CaR-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7oTWM2OD1{Lki2JO69VQ>? M1\hPXNCVkeHUh?=
NCI-H292 NHWzPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4KyPWlEPTB;Mj64OlU6PiEQvF2= NEn5UnRUSU6JRWK=
8305C M{S3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXNO5N{UUN3ME2yMlg3PjR3IN88US=> NUHWfoZHW0GQR1XS
SNU-449 NV\zepZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUiwV5ZQUUN3ME2yMlg6OTh{IN88US=> M2CzeXNCVkeHUh?=
LCLC-103H MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3remhIUUN3ME2yMlkxPDN6IN88US=> M1TOT3NCVkeHUh?=
SW1573 NYX4dYcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILxN2NKSzVyPUKuPVYxQDJizszN MmjIV2FPT0WU
MLMA NHnOSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJwOU[3NVch|ryP NVnPeJpRW0GQR1XS
NCI-H1355 NUDGb3NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTNwMEC3PVYh|ryP MVjTRW5ITVJ?
RMG-I NEnzS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPpTnk4UUN3ME2zMlAzPTl{IN88US=> MlroV2FPT0WU
BB65-RCC MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD2TWM2OD1|LkCzN|E1KM7:TR?= M4PofXNCVkeHUh?=
PC-3 NXvUdZpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTwTWM2OD1|LkCzPFc1KM7:TR?= MlTxV2FPT0WU
SF268 MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTNwMES1NlMh|ryP M4TYcnNCVkeHUh?=
NCI-H810 MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYOxOVdGUUN3ME2zMlA1QDJ|IN88US=> NVriXlY2W0GQR1XS
MEG-01 NGPxToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\BTWlEPTB;Mz6wOlE3PCEQvF2= NI\hbWhUSU6JRWK=
SW13 Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHIcZF[UUN3ME2zMlA4QDR5IN88US=> Ml\1V2FPT0WU
RH-1 NXnLW4luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zZZWlEPTB;Mz6xNFI4QCEQvF2= M1qydHNCVkeHUh?=
GT3TKB M4rJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P4VWlEPTB;Mz6xNVI5OyEQvF2= M2W5eHNCVkeHUh?=
TK10 NF3WZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTNwMUO3NlQh|ryP NGHGXIlUSU6JRWK=
T-24 M1rUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\XTWM2OD1|LkG1NFch|ryP M4iwSHNCVkeHUh?=
A498 NILheJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUSxZWxUUUN3ME2zMlIxQDdzIN88US=> MXHTRW5ITVJ?
GR-ST M1y2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTBT5BKSzVyPUOuNlIyOzlizszN MlL1V2FPT0WU
LB2518-MEL NXG3[pg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYOyZ3VrUUN3ME2zMlIzOzl6IN88US=> MUjTRW5ITVJ?
T47D MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLVTWM2OD1|LkKzOlI4KM7:TR?= MoKxV2FPT0WU
NCI-H1651 MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfwfWt7UUN3ME2zMlI1PjR2IN88US=> NWjKXVJwW0GQR1XS
EC-GI-10 NXXKPZNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX3TWM2OD1|LkK2NVU{KM7:TR?= NHjL[IJUSU6JRWK=
HT-29 MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojQTWM2OD1|LkK2OlE1KM7:TR?= NVvCXlJPW0GQR1XS
GI-ME-N M{\nWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXXdmhKSzVyPUOuNlk2OTFizszN NGTrWW9USU6JRWK=
SW756 NGjKSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TsUWlEPTB;Mz6yPVYzQSEQvF2= M{eyWHNCVkeHUh?=
RKO NFPkUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfGUldUUUN3ME2zMlMxPzV5IN88US=> M1jBVHNCVkeHUh?=
NCI-H1563 NILrVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P2cWlEPTB;Mz6zN|AyQCEQvF2= Ml\pV2FPT0WU
DJM-1 NHj5bVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TuWmlEPTB;Mz6zO|Y4PCEQvF2= M3nUSnNCVkeHUh?=
L-428 M{\OO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XlW2lEPTB;Mz60NFA1PSEQvF2= MXfTRW5ITVJ?
NCI-H2122 NYfhTolmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;GOIVKSzVyPUOuOFE{OTJizszN MmTZV2FPT0WU
Ca-Ski NImxbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\PU2lEPTB;Mz60OVQ{KM7:TR?= MYfTRW5ITVJ?
639-V MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq1c49KSzVyPUOuOFYxPTdizszN MVjTRW5ITVJ?
SW1116 NGLDVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTNwNE[yOlkh|ryP NVXMcoFJW0GQR1XS
DMS-114 NYLEdmd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrSTJhKSzVyPUOuOFcxPjZizszN MVXTRW5ITVJ?
MZ2-MEL NYnJfnRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTNwNEe2PFEh|ryP M1Kxb3NCVkeHUh?=
COLO-829 MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXWTWM2OD1|LkWwNFc{KM7:TR?= M3zqR3NCVkeHUh?=
J82 M3vGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{KyO2lEPTB;Mz61NFU4KM7:TR?= MlrCV2FPT0WU
EW-13 Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnXV41KSzVyPUOuOVI2OSEQvF2= M2noS3NCVkeHUh?=
RXF393 NGnxZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjrPXBKSzVyPUOuOVMzQTRizszN MVTTRW5ITVJ?
CAL-62 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTNwNUS1NVQh|ryP MofjV2FPT0WU
OCUB-M MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW3WVlSUUN3ME2zMlU1PjZ3IN88US=> M{\KTnNCVkeHUh?=
BT-474 Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO4fHdKSzVyPUOuOlM{OSEQvF2= MkLtV2FPT0WU
KYSE-180 NGf2ZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DsU2lEPTB;Mz62N|M4OiEQvF2= MoPTV2FPT0WU
NCI-H650 MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PvWGlEPTB;Mz62OFI5PyEQvF2= MXrTRW5ITVJ?
Detroit562 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz5TWM2OD1|Lk[1NFIzKM7:TR?= MXLTRW5ITVJ?
SW48 M1;CZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTNwNkW2OVch|ryP MYPTRW5ITVJ?
KYSE-450 NV:5flRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTNwNki1PFIh|ryP MofBV2FPT0WU
KYSE-510 MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTNwN{KxPFEh|ryP M1Hk[3NCVkeHUh?=
GP5d NIHJUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LKNmlEPTB;Mz63Nlk2KM7:TR?= MXnTRW5ITVJ?
RPMI-7951 NIeyN|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTNwN{S3NlMh|ryP NUH6[ow4W0GQR1XS
Becker M1TpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnETWM2OD1|Lke1NFEzKM7:TR?= MkXrV2FPT0WU
WM-115 NXLCRm0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTNwN{ixPVUh|ryP MnHhV2FPT0WU
G-401 M2q4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;uXpFKSzVyPUOuO|kxQDVizszN MmPSV2FPT0WU
PANC-08-13 M{Tsc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvLSG5KSzVyPUOuO|k3ODJizszN MWfTRW5ITVJ?
SW982 NUDaT4dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\aTWM2OD1|LkiwOVUyKM7:TR?= NYnvd3NDW0GQR1XS
D-263MG NXzlR2Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KxTGlEPTB;Mz64NlA2OSEQvF2= NH7TbXZUSU6JRWK=
KM-H2 NG\4eYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTNwOEK2NlQh|ryP NX\rR3p6W0GQR1XS
SK-MEL-3 M1;xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr2UY57UUN3ME2zMlgzQDRzIN88US=> M3jGOnNCVkeHUh?=
NCI-H1581 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7NTWM2OD1|Lki0OFg5KM7:TR?= NIfNW49USU6JRWK=
LS-123 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3eyU2lEPTB;Mz64O|kxQSEQvF2= NVPp[WxJW0GQR1XS
CAKI-1 Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon1TWM2OD1|Lki5NFUzKM7:TR?= M4Lue3NCVkeHUh?=
MEL-JUSO MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfzTWM2OD1|Lki5NVU{KM7:TR?= M2PvZnNCVkeHUh?=
HCE-4 NVHhbmI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTNwOUG2OlMh|ryP M1m4TXNCVkeHUh?=
TE-10 M3XpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG3TWM2OD1|LkmyNFEh|ryP MofUV2FPT0WU
OVCAR-4 MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW4RWhpUUN3ME2zMlkzQDh7IN88US=> NEDmXY5USU6JRWK=
ETK-1 NYPHRWM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13CXWlEPTB;Mz65OFY{PSEQvF2= NXrRUo5kW0GQR1XS
A2780 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3LUJNsUUN3ME20MlA2QTZ4IN88US=> MmjWV2FPT0WU
LU-65 NHGxcJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K3OWlEPTB;ND6wO|Y{OyEQvF2= M{jn[XNCVkeHUh?=
BHY NV;HToNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zpVGlEPTB;ND6xNlQ6PSEQvF2= M37KdnNCVkeHUh?=
COR-L105 M2r0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S5eWlEPTB;ND6xN|A2OSEQvF2= NWL3Tpp1W0GQR1XS
CAL-12T MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjhTWM2OD12LkGzNVA{KM7:TR?= MWTTRW5ITVJ?
SCH M4jETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT2TWM2OD12LkG1O|Q{KM7:TR?= M3LzfXNCVkeHUh?=
CW-2 M1jMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnTdVNFUUN3ME20MlE6ODBzIN88US=> MkLBV2FPT0WU
HCC1806 M2G4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;yZ2NKUUN3ME20MlIxOzF{IN88US=> MnrSV2FPT0WU
KP-N-YN M4DlZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;0RpdIUUN3ME20MlIxQTJ5IN88US=> MmrZV2FPT0WU
T98G MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7QcmZKSzVyPUSuNlIyPTdizszN NXrXdll7W0GQR1XS
CAL-54 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jqSmlEPTB;ND6yNlM5OSEQvF2= MnnSV2FPT0WU
CAL-33 NVnsVFRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofFTWM2OD12LkKzNFY1KM7:TR?= M2fMV3NCVkeHUh?=
SNU-C2B MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Phd2lEPTB;ND6yOFc3QSEQvF2= M2W5S3NCVkeHUh?=
NUGC-3 NEWxWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTRwMkW1NFUh|ryP MVrTRW5ITVJ?
DOK M2Ht[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe3SFRKSzVyPUSuNlY2QTNizszN MUXTRW5ITVJ?
MMAC-SF MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rMWmlEPTB;ND6yOlg2QSEQvF2= MYjTRW5ITVJ?
KYSE-70 NGL6coZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PGPGlEPTB;ND6yPVM1KM7:TR?= Mk\yV2FPT0WU
A204 NYH2UYgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTRwM{W4NFMh|ryP NYLld|ZRW0GQR1XS
SCC-25 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjRfI9KSzVyPUSuN|U5OTlizszN MljGV2FPT0WU
EPLC-272H M1XqZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vmd2lEPTB;ND6zPFk2KM7:TR?= NYDYdnRyW0GQR1XS
CAL-120 M3rmWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUWxenZHUUN3ME20MlM5QTl{IN88US=> MYjTRW5ITVJ?
LS-513 M2LEbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rQfGlEPTB;ND60NlE6QCEQvF2= NF\l[FBUSU6JRWK=
CAPAN-1 M{jpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;ETZZKSzVyPUSuOFI{QDJizszN MnPnV2FPT0WU
ESS-1 NHrlXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XtfmlEPTB;ND60NlczPCEQvF2= NH3a[WRUSU6JRWK=
GMS-10 M3vzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rhTWlEPTB;ND60NlgyQSEQvF2= Mkf6V2FPT0WU
NCI-N87 NHu4dHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Sz[2lEPTB;ND61NFg3QCEQvF2= NHPFVJpUSU6JRWK=
HMV-II MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL4VnhKSzVyPUSuOVE4OyEQvF2= NHXr[JNUSU6JRWK=
COLO-741 NYTPcFlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHrU4pKSzVyPUSuOVU6QTRizszN MWHTRW5ITVJ?
MKN45 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTRwNUe3N|Ih|ryP MUnTRW5ITVJ?
OAW-28 NVLKN|dWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[4N41KSzVyPUSuOVg{QThizszN NWPKeppqW0GQR1XS
OCI-AML2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rUUGlEPTB;ND62OVI{QCEQvF2= MoXjV2FPT0WU
MDA-MB-231 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvrTWM2OD12LkewNlQ{KM7:TR?= NWXUNpJmW0GQR1XS
NCI-H1648 NFnyUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnITWM2OD12LkeyNlc{KM7:TR?= NYnEPFJUW0GQR1XS
NCI-H1792 NVjwdo9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LvdmlEPTB;ND63OlExPyEQvF2= MV;TRW5ITVJ?
GCIY MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTRwN{e0NlQh|ryP NXnk[nV[W0GQR1XS
Hs-578-T NET1NJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTRwN{e2OVUh|ryP NFu4XmtUSU6JRWK=
SW962 MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLNV3ZTUUN3ME20Mlc5ODFzIN88US=> Mo\KV2FPT0WU
NCI-H630 NIP0[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zNTGlEPTB;ND63PFA5OSEQvF2= Mo\UV2FPT0WU
786-0 M3PWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTPbVh5UUN3ME20Mlc5Pzd|IN88US=> NIjTO5BUSU6JRWK=
FTC-133 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{exOWlEPTB;ND63PVI3OyEQvF2= NFjrNlRUSU6JRWK=
BT-20 Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\6O3lNUUN3ME20Mlc6PDJ7IN88US=> NWj5RmF1W0GQR1XS
Mewo NHTpcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\TTWM2OD12LkixO|Q4KM7:TR?= M2fKRXNCVkeHUh?=
SW780 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTRwOEW3OlYh|ryP NHvXOZlUSU6JRWK=
OE33 NXTvcGJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HDeGlEPTB;ND64O|cyOyEQvF2= M{T6V3NCVkeHUh?=
HCC1569 MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDDTWM2OD12Lki4OFU5KM7:TR?= NIXEPFVUSU6JRWK=
TE-6 NYnWOY02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\FWo15UUN3ME20Mlk{QTd5IN88US=> NUPE[oRzW0GQR1XS
SK-N-FI NFzCcG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDKb4xXUUN3ME20Mlk1PDJzIN88US=> NYq0R3dYW0GQR1XS
PANC-03-27 NEHVc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrqbHFKSzVyPUSuPVk6PjJizszN MVnTRW5ITVJ?
MCF7 Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTVwMEC3N|gh|ryP Mly4V2FPT0WU
UACC-257 MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTJTWM2OD13LkCyPFQ2KM7:TR?= MXPTRW5ITVJ?
SW1088 NYe0e21tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XQSWlEPTB;NT6wNlk1PCEQvF2= M3L6Z3NCVkeHUh?=
A704 NEe4dFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTVwMEOwOkDPxE1? M3\UXHNCVkeHUh?=
A2058 Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTVwMEW5NFgh|ryP NXfYXG1rW0GQR1XS
Calu-3 NHTLcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DTUmlEPTB;NT6wOlQ2OiEQvF2= Mlj0V2FPT0WU
RERF-LC-MS MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjmbY5KSzVyPUWuNFY6ODNizszN M3HOe3NCVkeHUh?=
AU565 MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW1bGxKSzVyPUWuNFk4ODJizszN MYrTRW5ITVJ?
DMS-79 NFO5XZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDxTWM2OD13LkGzPFg{KM7:TR?= MUPTRW5ITVJ?
DK-MG MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17zfmlEPTB;NT6xPFQ{QCEQvF2= M3LZWHNCVkeHUh?=
HuCCT1 MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rvRmlEPTB;NT6yN|g2PiEQvF2= M{S5ZXNCVkeHUh?=
HT-144 NWj4[ZV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPO[HQ6UUN3ME21MlI1QTh5IN88US=> M4mxSXNCVkeHUh?=
M059J MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTYVnlOUUN3ME21MlI2PzZizszN MkjNV2FPT0WU
COLO-792 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnzR45DUUN3ME21MlI3OzV4IN88US=> MlTPV2FPT0WU
SF539 NYTtbGR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTsdW5xUUN3ME21MlI3PjN{IN88US=> NV3Ne2l2W0GQR1XS
SK-UT-1 M163b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X3U2lEPTB;NT6yO|c2OSEQvF2= NWHnO|lzW0GQR1XS
NCI-H1703 NV;IUnpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXpWYFKSzVyPUWuN|U5OjZizszN NFzmRYpUSU6JRWK=
SW837 M3HvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nDcWlEPTB;NT6zO|g4QCEQvF2= NELoW25USU6JRWK=
U251 NXSxVndNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfZTWM2OD13LkO5NFk3KM7:TR?= Mkn5V2FPT0WU
SW1710 M4\HU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33XXGlEPTB;NT60NVU2PCEQvF2= NIrlZ5ZUSU6JRWK=
NCI-H1299 Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTVwNE[zN|Uh|ryP NESyXWlUSU6JRWK=
RVH-421 NELhSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;KVWlEPTB;NT60PVkxQCEQvF2= NGXUdFhUSU6JRWK=
UM-UC-3 NGm1WYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHO0epFKSzVyPUWuOlI3PTFizszN MYHTRW5ITVJ?
MDA-MB-175-VII M{DSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDjXYFKSzVyPUWuOlQxPDFizszN M{DTd3NCVkeHUh?=
KYSE-270 NHq0SI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTVwNk[wN|Eh|ryP Mnv1V2FPT0WU
COLO-668 NInrPWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjXTWM2OD13LkexN|Ih|ryP NYPHN2hlW0GQR1XS
LN-405 MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH3eoJKSzVyPUWuO|MxQDVizszN NHHNPHFUSU6JRWK=
HT-1376 M4L5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTpOoJKSzVyPUWuO|gxPTJizszN NIPDOolUSU6JRWK=
769-P MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfLeJE1UUN3ME21Mlg3PzF6IN88US=> NGKy[4NUSU6JRWK=
HuP-T3 NH\D[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHGTWM2OD13Lki4Olc4KM7:TR?= NXPG[JRTW0GQR1XS
MDA-MB-415 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfZ[5JVUUN3ME21MlkzOTN7IN88US=> M2H5SXNCVkeHUh?=
MKN7 M2XheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nXbmlEPTB;NT65PFgh|ryP M360Z3NCVkeHUh?=
KS-1 NWnNVHVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTVwOUi4N|Yh|ryP MULTRW5ITVJ?
647-V NFfpU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjMfGN1UUN3ME21Mlk6OTR6IN88US=> NV3w[FFsW0GQR1XS
COLO-679 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3XTJBKSzVyPU[uNFAzPTVizszN NFnRWZVUSU6JRWK=
AN3-CA NV7mTW9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W2VGlEPTB;Nj6wN|Q1OSEQvF2= NWPxW4JQW0GQR1XS
C32 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTZwMUOwN|Qh|ryP Mn:0V2FPT0WU
KM12 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\Heml2UUN3ME22MlI1ODl7IN88US=> M1KyeXNCVkeHUh?=
KINGS-1 NFLyZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfQTWM2OD14LkK2NVUzKM7:TR?= NVnwSZYzW0GQR1XS
KYSE-410 MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTZwM{C2OFUh|ryP Mm\sV2FPT0WU
HPAF-II NGOzWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvzbFRKSzVyPU[uN|U1QCEQvF2= NVfaW4lLW0GQR1XS
LAN-6 M37pOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvi[5RKSzVyPU[uOFk3OzFizszN MlnNV2FPT0WU
LU-99A NYTVTFdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTZwNUW5PFkh|ryP M{e0W3NCVkeHUh?=
SJSA-1 M2\1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELUOXlKSzVyPU[uOVY{PDdizszN M1[1VnNCVkeHUh?=
MSTO-211H NI\jdmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlexTWM2OD14LkeyNlM{KM7:TR?= M3rXNXNCVkeHUh?=
SW900 NUX1NoV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTZwN{[yNlEh|ryP MX3TRW5ITVJ?
LNCaP-Clone-FGC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDrfJJEUUN3ME22MlgxPDB|IN88US=> M1frNnNCVkeHUh?=
OMC-1 NYTlN2N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j4c2lEPTB;Nj64OVQxOiEQvF2= NIDTOppUSU6JRWK=
IST-MEL1 M4jVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;MTWM2OD14Lki5OlY6KM7:TR?= MUDTRW5ITVJ?
TE-9 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T0O2lEPTB;Nj64PVg1PyEQvF2= NWj2OI1SW0GQR1XS
NCI-H2030 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLjbGM{UUN3ME22MlkyOjJ4IN88US=> MVfTRW5ITVJ?
BFTC-909 Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHETWM2OD15LkCwOlQyKM7:TR?= MVTTRW5ITVJ?
NCI-SNU-5 NH7EW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTdwMEKxOVkh|ryP M{DmZnNCVkeHUh?=
TE-5 NIjDTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTdwMEK4PFEh|ryP M2\DUHNCVkeHUh?=
SK-MES-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTdwMEW0Nlch|ryP M{PURnNCVkeHUh?=
SHP-77 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHCTWM2OD15LkGzPVUzKM7:TR?= M4rjbnNCVkeHUh?=
NCI-H1623 NYr5Wm82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn0dHZKSzVyPUeuNVQxPzJizszN NYfpdVVDW0GQR1XS
TE-11 M4XyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf2RWJKSzVyPUeuNVUyQDRizszN MVnTRW5ITVJ?
EKVX MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFy2[4JKSzVyPUeuNVkzPjdizszN NYPSfmFRW0GQR1XS
OVCAR-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn3PWJKSzVyPUeuNlEyOzNizszN Ml7jV2FPT0WU
C3A NHrPfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW0TWM2OD15LkO0OVIh|ryP NYPzXJZtW0GQR1XS
CFPAC-1 NFOzT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS1bnpKSzVyPUeuN|YzOjJizszN MVHTRW5ITVJ?
MG-63 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTFVoVjUUN3ME23MlQyQDR7IN88US=> NV7OXpdYW0GQR1XS
KYSE-140 NIjJPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;GTWM2OD15LkS0NFYyKM7:TR?= NX\TelN2W0GQR1XS
MPP-89 NXfRflRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLpV3ZKSzVyPUeuOVk4OjlizszN NVzwTFAxW0GQR1XS
COLO-824 MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn2zTWM2OD15LkeyPFY{KM7:TR?= MofyV2FPT0WU
SiHa MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXRTWM2OD15LkizO|A4KM7:TR?= MXvTRW5ITVJ?
SNU-387 MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTdwOEWzOFch|ryP MUDTRW5ITVJ?
A172 M2TUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD0Vo1KSzVyPUeuPFYyPzJizszN Ml;XV2FPT0WU
COLO-680N Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTdwOUG3N{DPxE1? MlS1V2FPT0WU
HCC1395 M3jSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LzbmlEPTB;OD6wOVQ2OiEQvF2= NVf3NlNCW0GQR1XS
NCI-H28 M1;NN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRThwMEW5OlMh|ryP M3Tpd3NCVkeHUh?=
LC-2-ad M{\kdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjHclFKSzVyPUiuNlE6OzdizszN NILrcYdUSU6JRWK=
S-117 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXw[YhKSzVyPUiuNlU{PTNizszN MmTsV2FPT0WU
NCI-H1838 NEHXPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRThwMkW3PFEh|ryP M1;wbHNCVkeHUh?=
PANC-10-05 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRThwM{ewOFch|ryP NGXLUZNUSU6JRWK=
KALS-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzVbJVVUUN3ME24MlUxQTJ6IN88US=> MVfTRW5ITVJ?
LS-1034 M2[zNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\3OoVKSzVyPUiuOVc1OzdizszN MmPQV2FPT0WU
TGBC1TKB NED6N5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD5TWM2OD16LkezOVM2KM7:TR?= NF3WVnNUSU6JRWK=
OE19 NGX4NFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3JUI0xUUN3ME24Mlc3OjZ{IN88US=> NHntd4hUSU6JRWK=
D-502MG Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu2VGdPUUN3ME24Mlc3QTl2IN88US=> M1XD[XNCVkeHUh?=
JEG-3 M3PGVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnWTWM2OD16Lke4OlE5KM7:TR?= MUXTRW5ITVJ?
DBTRG-05MG Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjwVWRKSzVyPUiuPFc2PjVizszN MUPTRW5ITVJ?
ME-180 NFzM[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjVPFIyUUN3ME25MlA3PzJ3IN88US=> M3\SbHNCVkeHUh?=
NCI-H1573 NEXYTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7HSnVDUUN3ME25MlExPTN{IN88US=> NHzNR3NUSU6JRWK=
HCC2998 MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LoOWlEPTB;OT6xN|Y5OSEQvF2= M4XEe3NCVkeHUh?=
ACHN M2H1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTlwMkS5O|Uh|ryP NWLjTmlKW0GQR1XS
D-392MG MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTlwMkW3NVUh|ryP MX\TRW5ITVJ?
no-11 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Dlb2lEPTB;OT6yOlAzQCEQvF2= MXjTRW5ITVJ?
KLE NEPKXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLSTWM2OD17LkOyNlMzKM7:TR?= Mn;NV2FPT0WU
Calu-6 M3ft[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTlwM{e1Nlgh|ryP NHztPWlUSU6JRWK=
LB831-BLC M3HVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfiZnpJUUN3ME25MlQ2OTdzIN88US=> MkHSV2FPT0WU
SW684 M{LLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLNRm1KSzVyPUmuOFYyOTZizszN M2fFcXNCVkeHUh?=
SH-4 Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf1TWM2OD17LkS5N|Y1KM7:TR?= M3jnWXNCVkeHUh?=
IST-MES1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LlNWlEPTB;OT61NVY1PCEQvF2= MkfWV2FPT0WU
Saos-2 Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnrWYlpUUN3ME25MlUzOTl3IN88US=> MYPTRW5ITVJ?
NCI-H2087 Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTle29KSzVyPUmuOlc{PTJizszN MoP5V2FPT0WU
SCC-9 M{HacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTlwN{G4NVYh|ryP M2XXNHNCVkeHUh?=
MFE-280 NF2yZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTCeFFVUUN3ME25MlczPzh3IN88US=> MmmzV2FPT0WU
BEN NEDSZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Px[GlEPTB;OT64NlE2QSEQvF2= MmnqV2FPT0WU
CP50-MEL-B M4ewR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTlwOUK0N|Ih|ryP MoLyV2FPT0WU
SK-MEL-28 NXv4NVNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLYdWFwUUN3ME2xNE4xOTl|IN88US=> MWrTRW5ITVJ?
NCI-H2452 M4XJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LyO2lEPTB;MUCuNVYh|ryP NUHCeWU4W0GQR1XS
NCI-H1395 NYC3O2NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkm1TWM2OD1zMD6xO|gh|ryP M{\hT3NCVkeHUh?=
NCI-H2052 M37jSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFyLkG4PFIh|ryP MVnTRW5ITVJ?
A375 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jpRWlEPTB;MUCuNlQ2OiEQvF2= M3fS[3NCVkeHUh?=
HCC38 NELJdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvIfIpKSzVyPUGwMlMzOiEQvF2= MoHTV2FPT0WU
LK-2 MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFyLkSyNFgh|ryP NGm2UXFUSU6JRWK=
SF126 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\a[ZczUUN3ME2xNE41PzJ5IN88US=> M2rXOXNCVkeHUh?=
SK-MEL-1 M{f2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTFyLke4N|gh|ryP MV\TRW5ITVJ?
ACN M1jFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPITWM2OD1zMD64Olc6KM7:TR?= MX\TRW5ITVJ?
BB30-HNC NGe2dFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLBe2FRUUN3ME2xNE45PzFzIN88US=> MnPDV2FPT0WU
NCI-H747 NHzGclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXZeGV7UUN3ME2xNE45PzR4IN88US=> NIDoe3NUSU6JRWK=
KYSE-150 M{fCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m1TGlEPTB;MUGuNFM5PyEQvF2= MnTNV2FPT0WU
D-247MG M{eyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFzLkGwNFkh|ryP NELFTW1USU6JRWK=
BxPC-3 NUW4PXd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnTTWdKSzVyPUGxMlM4PDdizszN NYLndFV{W0GQR1XS
SK-MEL-30 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu4clZKSzVyPUGxMlQxPzlizszN MXrTRW5ITVJ?
CAS-1 NUnDVmhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFzLkSxNFkh|ryP MlXUV2FPT0WU
no-10 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD4TWM2OD1zMj6xNlE4KM7:TR?= MUjTRW5ITVJ?
NCI-H2405 Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXpbZdKSzVyPUGyMlIxOzZizszN NESwSZZUSU6JRWK=
KGN NH7EVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnwTWM2OD1zMj6yPVAyKM7:TR?= NFrLTYVUSU6JRWK=
BB49-HNC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjnN45KSzVyPUGyMlM6PTZizszN MVrTRW5ITVJ?
NCI-H1693 NXT0T|ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7jO|hJUUN3ME2xNk42QDF4IN88US=> MY\TRW5ITVJ?
RO82-W-1 M{HGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\ocFNKSzVyPUGzMlA3PDlizszN NH;2WpBUSU6JRWK=
CAL-85-1 NV;N[pdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jPS2lEPTB;MUOuOFM6QSEQvF2= MYHTRW5ITVJ?
H-EMC-SS NWfsPZFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzWTWM2OD1zMz65NVA1KM7:TR?= MX;TRW5ITVJ?
SW1783 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF2LkKzPVEh|ryP NH3iblhUSU6JRWK=
LB771-HNC NELFN3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT6R|hwUUN3ME2xOE41OTlizszN MnfoV2FPT0WU
HCC70 M4\Kcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LzOWlEPTB;MUSuOFI{OyEQvF2= NHz2OHZUSU6JRWK=
KNS-81-FD NYTZPIxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LTNmlEPTB;MUSuO|A1PSEQvF2= MlXKV2FPT0WU
KYSE-520 M32wOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF2LkmyO{DPxE1? MoTrV2FPT0WU
TGBC24TKB NWLYcmRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjhV|dKSzVyPUG0Mlk2OzlizszN MV7TRW5ITVJ?
SNB75 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{foZmlEPTB;MUWuNFczQSEQvF2= M2PYfXNCVkeHUh?=
SW872 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF3LkKyNVgh|ryP M3XifXNCVkeHUh?=
U031 MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTUVIdKSzVyPUG1MlgxOjhizszN M1LMe3NCVkeHUh?=
ChaGo-K-1 M3T3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLHenZDUUN3ME2xOU45OzV7IN88US=> NXHtdoZGW0GQR1XS
NCI-H441 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33kVmlEPTB;MU[uNFA{QSEQvF2= NGD4ZZhUSU6JRWK=
TE-12 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTF4LkG4O|Mh|ryP M3nYPHNCVkeHUh?=
NCI-H1755 NXTMfpl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[yNFVKSzVyPUG2MlU4OyEQvF2= MXPTRW5ITVJ?
KNS-42 M4\wdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTF4Lk[1PFkh|ryP M3PiTHNCVkeHUh?=
SK-PN-DW M4XQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XTW2lEPTB;MUeuOFIxOSEQvF2= NUjrdnM{W0GQR1XS
NCI-H226 MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rFTGlEPTB;MUeuPVM1PSEQvF2= NU\LO3JPW0GQR1XS
K-562 NFfUSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XX[GlEPTB;MUiuOlMyPyEQvF2= NIfYNnhUSU6JRWK=
A388 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljKTWM2OD1zOT6wN|A{KM7:TR?= NU\z[JZyW0GQR1XS
ZR-75-30 MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTYcIh3UUN3ME2xPU4xQTZ6IN88US=> MX\TRW5ITVJ?
LU-135 NXrCZphWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jKdmlEPTB;MUmuNlY{PiEQvF2= NFXjNZhUSU6JRWK=
NCI-H2029 NWX4[JJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7JTWM2OD1zOT62NFIyKM7:TR?= MorYV2FPT0WU
HT-1197 MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfLblVKSzVyPUG5MlkzOjdizszN Mm\SV2FPT0WU
IGR-1 NFv3RpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;VTWM2OD1{MD6zNVE4KM7:TR?= NH;v[VRUSU6JRWK=
U-87-MG NU\6VnNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVridphEUUN3ME2yNE43PDF|IN88US=> MnrEV2FPT0WU
NCI-H1304 MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmmwTWM2OD1{MD63OVAyKM7:TR?= M17YN3NCVkeHUh?=
RCC10RGB NYr0TYJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rZZWlEPTB;MkGuNlgzQSEQvF2= NHXrV|ZUSU6JRWK=
NCI-H520 M2\CSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzoe4hKSzVyPUKyMlc3OTFizszN NHPUTVZUSU6JRWK=
SK-LU-1 NYjaTItXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnWW|dKSzVyPUKzMlA4OThizszN NFzYS4hUSU6JRWK=
UACC-893 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnVfo03UUN3ME2yN{4yODN6IN88US=> M2mzTXNCVkeHUh?=
NCI-H2347 NGPsV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fkWGlEPTB;MkOuNlY4PCEQvF2= NXzZ[2JSW0GQR1XS
U-118-MG NHPI[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4OwdWlEPTB;MkOuO|IyPyEQvF2= NVK5dXJqW0GQR1XS
NCI-H596 M2XYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELp[5RKSzVyPUKzMlkxPTVizszN NWrtdlB[W0GQR1XS
MZ1-PC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zmT2lEPTB;MkSuOlc2QSEQvF2= Mm\6V2FPT0WU
SW1417 NVPYU2F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3wSIhKSzVyPUK1MlI1QThizszN NUWzXWFbW0GQR1XS
NCI-H82 NX;IeYpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vMcWlEPTB;Mk[uOFI5QCEQvF2= NG\VU5JUSU6JRWK=
COLO-678 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjKRW5KSzVyPUK3MlQ6OTlizszN M2XhUnNCVkeHUh?=
KURAMOCHI M{m4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPPO|hUUUN3ME2yPE4yOjZizszN MXLTRW5ITVJ?
NCI-H1650 MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;LW2lEPTB;M{CuNVkzPCEQvF2= MXLTRW5ITVJ?
HCC1954 NUnmVJQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjKTGJpUUN3ME2zNU4{PjZ4IN88US=> NHjRW3dUSU6JRWK=
GAK NIL1dWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjuTo1KSzVyPUOyMlI3OTZizszN NGX3Z25USU6JRWK=
YAPC M2qxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n1NGlEPTB;M{OuO|Y1QCEQvF2= MkfTV2FPT0WU
NCI-H2228 NXzFR2tRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn3SFBSUUN3ME2zOE4{PjB3IN88US=> NEC0dXdUSU6JRWK=
VMRC-RCZ MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7vT2RjUUN3ME2zOk4{ODJ{IN88US=> NGLFPHJUSU6JRWK=
NMC-G1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rROmlEPTB;M{euNFUzQSEQvF2= NF\sXpBUSU6JRWK=
D-336MG NXvRcnZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrnTWM2OD12MT64OFQzKM7:TR?= NFvpbnBUSU6JRWK=
UACC-62 MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTR{LkW1NFUh|ryP NE\I[|NUSU6JRWK=
C-33-A NWT2SXQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFOweItKSzVyPUS1MlMzPTZizszN MXXTRW5ITVJ?
HCC1937 M3r6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzVbFRKSzVyPUS3MlE6PThizszN MYrTRW5ITVJ?
HDLM-2 NXzsOWdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPWSYhKSzVyPUS3MlIzQDdizszN NGK4TIJUSU6JRWK=
NCI-H727 NF\mc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj3Vpo{UUN3ME20O{4zPDVzIN88US=> Mn\6V2FPT0WU
NY NV74VWJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rON2lEPTB;NEmuN|kxQCEQvF2= M1fZZnNCVkeHUh?=
NCI-H2291 NXfzeoFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK4OmI6UUN3ME20PU45OzBzIN88US=> NIHUdmpUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. [2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoprecipitation-HDAC assays:

The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an 3H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [3H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research:

[2]

+ Expand
  • Cell lines: LNCaP, PC-3, and TSU-Pr1
  • Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM
  • Incubation Time: 1, 2, 3 and 4 days
  • Method:

    Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells
  • Formulation: Dissolved in DMSO
  • Dosages: ~100 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 52 mg/mL (196.74 mM)
Ethanol 3 mg/mL (11.35 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 264.3
Formula

C14H20N2O3

CAS No. 149647-78-9
Storage powder
in solvent
Synonyms SAHA, MK0683, suberoylanilide hydroxamic acid

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03742245 Not yet recruiting Breast Cancer Metastatic|Breast Cancer Jenny C. Chang MD|AstraZeneca|The Methodist Hospital System March 1 2019 Phase 1
NCT03022565 Recruiting Uveal Melanoma University of Miami|University of Miami Sylvester Comprehensive Cancer Center December 2018 Early Phase 1
NCT03263533 Recruiting Schizophrenia Virginia Commonwealth University December 1 2018 Early Phase 1
NCT03259503 Not yet recruiting Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Lymphoma M.D. Anderson Cancer Center|AstraZeneca November 2018 Phase 1|Phase 2
NCT03713320 Recruiting Cutaneous T-Cell Lymphoma/Mycosis Fungoides miRagen Therapeutics Inc. October 2018 Phase 2
NCT03382834 Active not recruiting HIV Infections National Institute of Allergy and Infectious Diseases (NIAID) April 26 2018 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommendation about reconstitution of the compound for in vivo animal study?

  • Answer:

    We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Vorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683) supplier | purchase Vorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683) cost | Vorinostat (SAHA, MK0683) manufacturer | order Vorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID